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Summary 
Neurodegnerative disordes like Alzheimer disease, Parkinson disease and infec-
tious prion diseases pose a significant threat to human health. Recent research 
associates these diseases with corruptive protein templating or seeding.
1
 Interaction 
of protein monomers with their misfolded confomers, or seeds, induces a confor-
mational alteration which resembles seeded crystallization.
2
 The presumably self-
perpetuating mechanism leads to seed amplification as the pathogenic aggregates 
corrupt more and more benign monomers over time. The first example of a self-
templated protein misfolding was given by mammalian prion diseases, such as 
scrapie in sheep, BSE (bovine spongifrom encephalopathy) in cattle or new variant 
CJD (Creutzfeldt-Jakob disease) and kuru in humans.
3
 It was demonstrated that 
prion infectivity can be maintained infinetely in vitro if periodic ultrasound pulses 
are used, a technique called Protein Misfolding Cyclic Amplification (PMCA).
4
 In 
this context, it was proposed that prion amplifcation in vitro is promoted due to 
periodical fragmentation of the seeds.
5
  
We successfully used PMCA to amplify Sc237 hamster prions, but also revealed the 
limitation of the method regarding its reproducibility. Based on conformation 
sensitive seed fragmentation we therefore developed the concept of Selective 
Shearing Amplification (SSA), which achieves seed fragmentation by fine-tuned 
shear forces in vitro. We hypothesized that conformational seed polymorphisms 
imply different structural stabilities. Thus, uniform seed populations might be 
conformationally selectable from natural, potentially mixed seed populations. 
Starting from a mixture SSA confers a selective advantage for optimally fragmented 
seeds which then become the dominant species. As opposed to this, seed 
populations which show a distinct mechanic fragmentability are suppressed. To 
validate the concept of SSA we surveyed the amplification of the closely related 
hamster prion strains Sc237 and 263K using a new ultrasonic as well as a 
mechanical approach. In ultrasonic SSA the shear forces are modulated by the 
distance of the reaction vials from the sound source. Furthermore the vibrational 
behavior of the used sonotrodes was considered. The experiments revealed that 
there is a clear distinction between both prion strains. In contrast to the ultrasonic 
approach, mechanical SSA is based on Couette-flow which generates a constant 
shear stress. Additionally, the technique makes it possible to test various parameters 
in parallel. Interestingly, the data showed to be in line with the results from 
ultrasonic SSA. While multiple seed conformations were detected in the Sc237 
strain, mechanical SSA experiments with the cloned prion strain 263K revealed 
6 1 Introduction 
only one detectable seed population. Furthermore, the presented method provides a 
way for kinetic seed amplification acquisition. Indeed, the kinetic seed ampli-
fication traces of the surveyed prion strains also showed clear differences. Thus, we 
concluded that the prion strain Sc237 is comprised of conformationally different 
seed populations.  
Unfortunately, the underlying mechanisms of self-templated protein conversion 
remain elusive and the molecular structures of proteopathic seeds are still unknown. 
The concept of selective shearing amplification is not limited to prions and the 
identification and characterization of specific seed populations using SSA could 
provide a significant benefit to current research. The presence of more than one 
seed conformation, for example, might also be true for human neurodegenerative 
diseases like Alzheimer disease or Parkinson disease which have also been 
associated with proteopathic seeds. Using the conformation sensitive concept of 
SSA a future application could be the generation of kinetically selected, 
homogeneous seed preparations for detailed structural investigations. 
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1 Introduction 
1.1 Transmissible spongiform encephalopathies 
Transmissible spongiform encephalopathies (TSEs) are infectious, progressive 
disorders that affect the central nervous system. These inevitable fatal diseases are 
characterized by long incubation times. The typical course of the disease is asso-
ciated with a vacuolization of the grey matter. Beside astrogliosis – a proliferation 
of astrocytes – protein aggregates can be observed. Also neural cell loss, caused by 
apoptosis, and meningitis are described.
6–9
 Distribution and intensity of histo-
pathologic abnormalities strongly depend on cell tropism, toxicity, the hosts neural 
anatomy as well as its genetics.
7,10
 Several examples for TSEs in human and 
animals are given in Table 1.1.  
Table 1.1:  Mammalian TSEs
11
 
Disease Abbrevation Species Incidence Etiology 
Creutfeldt-Jakob 
disease 
fCJD 
sCJD 
vCJD 
Human 
Familial 
Sporadic 
iatrogenic 
Prnp mutation 
? 
Infection 
Gerstmann-
Sträussler-
Scheinker 
syndrome 
GSS Human Familial Prnp mutation 
Fatal familial 
insomnia 
FFI Human Familial Prnp mutation 
Bovine spongiform 
encephalopathy 
BSE Cattle Iatrogenic Infection 
Scrapie  
Sheep/goats 
Mouse (adapted) 
Hamster (adapted) 
Iatrogenic 
Infection 
Experiment 
Experiment 
Chronic wasting 
disease 
CWD Elk/Mule deer Iatrogenic Infection 
 
The Creutzfeldt-Jakob disease (CJD) is the most common TSE in human. However, 
only one incidence in a million occurs. It was discovered by H.G. Creutzfeldt in 
1920. One year later several cases of the disease were described by A. Jakob. Four 
forms of CJD are known: The sporadic (sCJD), the familiar (fCJD), the iatrogen 
(iCJD) and the variant form (vCJD). About 85% of the CJD cases are sporadic and 
occur in human at the age of 50 to 75 years. Besides dementia the disease impairs 
the speaking ability, the movement and is often accompanied by muscle 
convulsions. First symptoms are usually forgetfulness, a loss of general interest and 
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social contacts as well as changes in eating and sleeping behavior. As the illness 
progresses, irregular walking, vision changes, slow talking and hallucinations can 
occur. Furthermore, incontinence and totally involuntary movements appear. 
Sporadic CJD usually leads to death one year after diagnosis.
12–15
 The familial CJD, 
in contrast, is inherited and concerns only 10-15% of all CJD cases. Patients with 
fCJD are often younger than sCJD patients and carry specific mutations of the Prnp 
gene (cp. 1.6, p. 27 et seqq.).
16,17
 The course of fCJD is longer compared to the 
sporadic form and the typical symptoms vary more. While sCJD and fCJD just 
appear or are genetically predisposed, iatrogen CJD is caused by contact with the 
infectious agent during medical procedures (gr. iatr, iater = doctor; genes, genet = 
genesis). Indeed, it was shown that contaminated surgical instruments pose a risk to 
patients and the effictivity of common decontamination techniques was 
questioned.
18,19,20,21,22
  
In the year 1996, during the BSE-crisis, a new variant of CJD was firstly 
described
23
 and until August 2012 173 cases were recorded.
24
 Contrary to other CJD 
forms, the pathology of vCJD turned out to be considerably different: extensive 
amyloid plaque formation can be found in the cerebrum and the cerebellum.
23,25,26
 
The protein deposits are often surrounded by vacuoles, also referred to as florid 
plaques.
27
 In sCJD and fCJD these protein plaques are rarer and occur in clusters of 
Purkinje cells. In contrast, the plaques in iCJD spread across the whole brain. 
Symptoms in vCJD can reach from lightly depressions and psychosis
28
 to painful 
sensory abnormalities, ataxia and involuntary movements. Unlike sCJD the course 
of the disease is longer and the patients are younger – averaging out at 27 years. 
Based on the atypical clinical course of the diesase as well as other biomolecular 
evidences
25,29,30
 it was proposed that vCJD is a direct consequence of BSE trans-
mission via contaminated food sources. Indeed, transmission studies with macaques 
found evidence that BSE isolates can cause vCJD
31
, while further experiments 
revealed identical transmission characteristics between BSE and vCJD.
30,32
 
The Gerstmann Sträussler Scheinker syndrome (GSS) is a familial disease. The 
heredity is autosomal dominant and clinical signs emerge within an age of 30 to 40 
years. Mutations of the Prnp gene (cp. 1.6, p. 27 et seqq.) are regarded to be the 
triggers of the disease. The course of GSS covers a period of up to five years. 
Typical symptoms are ataxia, spasms and dementia.
33,34
 Like GSS the fatal familial 
insomnia (FFI) can be inherrited, but also sporadic cases have been reported.
35
 
Insomina, dysautonomia (malfunction of the autonomic nervous system), dementia 
as well as phobia and panic attacks characterize the course of FFI that inevitable 
ends with the death after 7 to 15 months.
36
 Similar to GSS, spongiform abnor-
malities can be observed and the thalamus shows atrophies. Nevertheless, the 
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clinical signs are hard to distinguish from CJD. Thus, it is difficult to reach a 
definitive diagnosis.
37
 
Contrary to CJD, GSS and FFI, kuru has been well-described for a couple of 
hundred people in a district of Papua New Guinea. Dementia is a typical symptom 
of CJD. However, although symptoms like ataxia, uncoordinated movements, 
blackouts, general weakness and decreasing cortical capacity have been associated 
with kuru, dementia has not been observed. A characteristic of kuru are pathologic 
bursts of laughter. Thus, the name “The laughing death” has become established. 
C. Gajdusek revealed an oral human-to-human transmission of the kuru-agent in the 
wake of cannibalism.
38,39
 By ritual eating of their death the local natives were 
exposed to high-amounts of infectious material. It was thus hardly surprising that 
the symptoms also affected children which indicated that the incubation periods are 
significant shorter than it was known from the sporadic or familial forms of CJD.  
TSEs are widespread under mammalian species, for instance they were described in 
sheep, goats, minks, mule deer, feline species and ungulates. Apart from the bovine 
spongiform encephalopathy the most extensive studies have been made on scrapie 
and the chronic wasting disease (CWD). Scrapie is known to affect goats and sheep 
and first records of its existence date back to the 18
th
 century.
40
 Strong itching 
sensation, leading affected animals to scrape off their wool or hair, is followed by 
ataxia, excitability and lack of interest. Histological investigations of brains from 
scrapie affected animals showed strong similarities to CJD. By coincidence, the 
transmissibility of TSEs was first shown in the wake of the administration of 
vaccines to Scottish sheep
41
, but also transmissibility across species was observed, 
for example in mice
42
, rats
43
 and hamsters
44
. The chronic wasting disease of mule 
deer
45
 is an expanding problem in north America, spreading from Colorado to 
further states. While the origin of CWD is still unknown the disorder shows 
substantial impact on mule deer populations. 
The risk of CJD transmission due to surgical intervention or medical treatment is 
believed to be relatively low. Sporadic CJD seems to be limited to CNS tissue.
46–48
 
Thus, for instance, transmissions to primates have so far only been demonstrated 
using CSF fluids
49,50
 and peripheral nerves, tonsils, spleen, cervical lymph nodes, 
appendix, kidneys, liver, lung and heart muscle have been tested negative for 
transmissibility.
48
 Furthermore, in vivo transmission studies have shown that 
peripheral nerves, intestine, bone marrow, blood, skeletal muscles, adipose tissues 
and also excretions seem to be non-infectious.
49
 However, the situation is different 
with vCJD. Contrary to sporadic and familial CJD, GSS and Kuru not only CNS 
tissue was demonstrated to be infectious. For expample, the infectivity of lymphatic 
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tissues (spleen, lymph nodes, tonsils) and the gastrointestinal tract has been 
demonstrated uniquely for the variant form of the Creutzfeldt-Jakob disease.
46,48,51–
53
 This suggests a higher risk for iatrogenic CJD, but so far only three cases have 
been reported. Interestingly, the iatrogenic CJD of these individuals is likely to be 
caused by blood transfusion.
48,54,55
 Regarding the low number of cases and the fact 
that infectivity could not be substantiated for blood plasma and buffy coat samples
51
 
the risk of transmission via blood transfusion can be considered as relatively low. 
Nevertheless, the british government assessed the risk as high for blood transfusion 
recipients of certain time intervals and in certain risk groups, like haemophiliacs. 
The vast majority of iatrogenic CJD cases resulted from an exposure to high-titer 
tissues, like infectious brain, dura mater and cornea or was attributable to treatments 
with pituitary homones and is rather caused by transmissions of sporadic CJD.
19,56
 
However, the appearance of the variant form was discussed heavily within the scope 
of a diet-related transmission, but up till August 2012 not more than 173 vCJD 
cases have been reported in the United Kingdom.
24
 After the BSE crisis, the 
outbreak of vCJD was an often discussed scenario, but fortunately it did not become 
reality and over the years predicted numbers were corrected downwards. 
It was argued that a genetic predisposition might influence the progression of the 
disease because the majority of the vCJD patients was homozygous for methionine 
129 in the human Prnp gene on chromosome 20. In addition, the Prnp codon 129 
genotype frequencies show different distributions for sCJD, vCJD and the normal 
population. Furthermore, the genotypes seem to be correlated to the transmission 
pathway. Patients which have been transmitted directly showed to be homozygous 
for methionine. A peripheral transmission (e.g. by hormone therapy) causes a longer 
incubation time in the heterozygous case. Interestingly, the polymorphism has no 
effect on the incubation time of transplant recipients. In view of the fact that TSE 
incubation periods can last several years and clinical symptoms can be attenuated, 
the susceptibility of heterzygous genotypes (Met/Val), but also for Val/Val might 
not be zero.
18,57–61
 Thus, it is hard to define the risk of iatrogenic transmission, 
especially for variant CJD.  
Without doubts effective and safe decontamination is of prime importance to 
prevent human-to-human transmssions via surgical instruments. TSE agents show a 
high resistance to heat, UV-radiation and enzymatic degradation. Especially their 
high binding affinity to steel surfaces poses problems
20,56
 and necessitates specific 
decontamination procedures. Treatments that are considered appropriate for 
decontamination include the use of sodium hydroxide or hypochlorite, but also the 
decontamination effects of alkaline detergents, phenolic agents and different 
autoclaving procedures have been surveyed. Even the effect of gas plasma was 
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tested.
20,62–67
 The World Health Organisation (WHO) for example, recommends an 
hour-long treatment of heat-resistant instruments, wastes and materials which were 
directly exposed to high or low-infective tissues with 1N NaOH or hypochlorite 
(20,000 ppm) followed by autoclaving at 121 or 134°C. For disposable materials an 
incineration is proposed while heat-sensitive instruments should be treated with 2 N 
NaOH or undiluted hypochlorite for 1 hour.
68
 A summary of efficient decontami-
nation methods is given in Table 1.2.  
Table 1.2: Typicial prion decontamination protocols with a log reduction larger than five
56,62
   
Method Parameters 
Chemical 
20,000 ppm NaOCl at 20°C for 1 h 
1N NaOH at 20°C for 1 h 
Alkali 
Hamo 100 Prion inactivation detergent (Steris) 1.6% (v/v) at 43°C 
for 15 min 
Phenolic Environ LpH 5% (Steris) at 20°C for 15 min 
Autoclaving Autoclaving at 134°C for 18 min, immersed in water 
Enzymatic 
Kienzyme (Steris, 1.4 mg/ml at 25°C for 3 h)  
and vaporized hydrogen peroxide (0.8% (v/v) at 43°C for 5 min) 
1.2 The protein only hypothesis 
The transmissibility of TSEs was discovered by pure chance in 1937 (cp. 1.1) and 
was initially attributed to viral infection.
41,69–71
 It was Alper who showed that the 
molecular weight of the infectious agent deceeds the characteristics of a virus.
72
 
Furthermore, a high resistance against radiation and digests with DNAse and 
RNAse substantiated the absence of a nucleic acid in the TSE agent.
73–75
 Initially 
declared as a ‘slow virus disease’ the facts were more and more shaking existing 
dogmas and a proteinaceous cause was dicussed controversially. A cascade of facts 
suggested that the infectious agent is mainly consisting of protein. For instance, the 
infectivity could be decreased using protein inactivation methods. Moreover, the 
aggregation behavior and its major localization in cell membranes indicated that the 
infectious agent mainly consists of protein.
76–82
 Nevertheless, the ‘protein only 
hypothesis’, which tried to explain the results of Alper83, was not completely 
accepted. For example, it was argued that nucleic acids are still involved, but are 
covered by compact and resistant protein coats.
84,85
 Finally, it was shown that the 
prion protein (PrP) forms the majority of TSE agent enriched samples. Today it is 
widely accepted that the disease associated, pathological form of the prion protein, 
PrP
Sc
, is the main if not only part of a ‘proteinaceous infectious particle’ or 
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‘prion’.86,87,88,89,90 In vivo-studies revealed that the infectious titer is directly 
correlated to the PrP
Sc
 concentration.  Furthermore, anti-PrP antibodies could 
reduce the infectivity of the TSE agent. In its altered state, PrP
Sc
 binds and converts 
its benign cellular isoform (PrP
C
) into likeness of itself (cp. 1.4, p. 19 et seqq.). Both 
forms are encoded by a single gene.
91
 However, chemical differences between these 
isoforms could not be shown using mass spectrometry and amino acid sequencing.
92
 
Nevertheless, PrP
Sc
 is enriched in β-sheet secondary structure, less soluble than its 
cellular form and able to form larger-order aggregates.
93–95
 Its precipitability by 
NaPTA (sodium phosphotungstic acid) or the exposure to certain epitopes allow to 
make further case distinctions. PrP
Sc
 shows a partial resistance to protease K digests 
(rPrP
Sc
), but also a susceptible form is known (sPrP
Sc
).
96–100
 The protease resistant 
core of PrP
Sc
, has an apparent molecular mass of 27-30 kDa (PrP
27-30
).
3
 However, 
protease resistance is not necessarily accompanied by infectivity, which caused the 
designation PrP
res
 (Figure 1.1). 
 
Figure 1.1:  Conversion of the cellular prion protein to its abnormal isoform 
The cellular prion protein (PrP
C
, simplified depiction of murine PrP without 
posttranslational modifications) can undergo a conversion to an aggregated, β-
sheet-rich isoform which can show partial protease K resistance (PrP
res
).   
 
The discussion on wether proteins can be infectious in the absence of nucleic acids 
continued to be controversial. Many studies supported the protein only hypothesis. 
An evident finding, for instance, was a TSE resistance in mice lacking the PrP gene. 
Additionally, it was shown that the susceptibility can be reconstituted by inserting a 
PrP transgene.
101
 It was also demonstrated that several PrP gene mutations are 
associated to familal TSEs.
3,15,102
 Still there was criticism: PrP overexpressing mice 
with GSS related mutations were shown to develop TSE similar symptoms 
including transmissibility
103,104
, but the experiment could not be reproduced
105
. 
Furthermore, in vivo-studies were formerly performed using transgene mouse 
models. In consequence PrP was overexpressed. Dwindling acceptance due to the 
possible toxic character of high PrP concentrations cast doubt on presented 
results.
106
 That the TSE agent might lack any nucleic acids was one of the central 
arguments of the ‘protein only hypothesis’. Nevertheless, there were uncertainties 
about the agent
3,107,108
: On the one hand it was demonstrated that RNA interacts 
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with the prion protein
109–111
 and promotes its conversion in vitro
112
, on the other 
hand infectious prions could be generated in the absence of any mamallian 
cofactors.
90
 
1.3 Prion strains and transmission barriers 
Generally, interspecies transmissions of TSEs are less efficient compared to intra-
species transmissions.
113
 This ‘species barrier’ is particularly reflected by prolonged 
incubation times and incomplete attack rates. Amino acid sequence deviations 
between donor and recipient species were the base of first attempts of explanation. 
The primary structure of PrP is highly conserved.
114,115
 Between hamster and mouse 
for example, the proteinase K resistant core of PrP
Sc
 exhibits only eight amino acid 
differences. However, hamster prions have no effect on wild-type mice, whereas 
transgenic mice, which express hamster PrP, are susceptible.
116
 Nevertheless, the 
barrier could be circumvented using transgenic mice which expressed a chimeric 
PrP (MH2M). These animals could be successfully transmitted with either hamster 
or mouse prions.
117
 Furthermore, prions which were generated in the chimeric 
mouse line transmitted disease to wild-type hamsters and mice. In another 
experiment transmission of classical CJD prions into wild-type mice failed, while a 
transmission into humanized animals was successful.
29,118
 Thus, the species barrier 
is attributable to the primary structure of the prion protein. 
It was hypothesized that resembling PrP sequences of donor (PrP
Sc
) and recipient 
(PrP
C
) might be a pressuposition for an efficient prion propagtion in vivo and 
polymorphism effects in sporadic and acquired CJD might be used as an argument: 
individuals, which are homozygous at residue 129 of PrP present the majority in 
vCJD case statistics.
18,57–61
 Thus, the term ‘sequence barrier’ might also be 
appropriate.
119
 Then again, experiments with human prions also indicated that 
cellular factors might play a role for successful transmission (cp. 1.4, p. 19 et seqq.). 
Nevertheless, prion infectivity can also vary if the amino acid sequence of host and 
donor is the same.
120
 For example, a ‘transmission barrier’121 was observed if 
humanized mice were inoculated with vCJD prions, while sCJD prions showed to 
be highly infectious.
29
 
In addition to the variations of the prion inter-species transmissibility described 
above, several phenotypic TSE variants were discovered in genitically identical 
mouse models.
122,123
 These prion strains show consistent characteristics if they are 
inoculated into distinct hosts, such as incubation times and brain lesion profiles 
(Figure 1.2 A). Moreover, the intrinsic properties of prions strain were also 
16 1 Introduction 
maintained after subpassages in other species (Figure 1.2 B).
124
 Nevertheless, 
changes of the PrP primary structure could not be shown in this context.
125
  
A possible clarification of the question how proteins can lead to different disease 
phenotypes was given by proteinase cleavage experiments with hamster prion 
strains. After proteolytic digestion of the prion strain isolates hyper (HY) and 
drowsy (DY) peptide fragments of different size were detected, which indicated 
conformational differences.
126–128
. Indeed, several prion strains could be identified 
and characterized using conformation-dependent immunoassays, digestion kinetics, 
denaturation experiments, metal binding analysis or IR spectroscopy.
98,129–131
 
Electrophoretic size separation of prion samples after protease K digestions showed 
different PrP
Sc
 glycoform ratios (un-, mono- and diglycosylated) and animal 
transmission experiments revealed that they are a consistent characteristic of prion 
strains. (Figure 1.2 A and B).
25,132
 Indeed, experiments with monoclonal PrP
Sc
- and 
gycosylation-specific antibodies have shown that glycoforms are physically 
associated to native PrP
Sc
 in strain-specific ratios.
133
 Hence, different disease 
phenotypes and variations of the prion inter-species transmissibility were attributed 
to the existence of polymorphic prion strains: assuming that a prion strain comprises 
multiple PrP
Sc
 conformations, the particular compatibilty of one or some 
conformations to the amino acid sequence of the host might trigger inter-species 
transmission, while less compatibility causes a species barrier or dramatically 
increases the incubation periods. Thus, the largest selective advantage determines 
the disease phenotype.
121
  Furthermore, the number of PrP
Sc
 conformations or 
strains might be limited by their thermodynamic stability and their replication 
kinetics which have to show a faster build-up than counteracting cell protein 
degradation processes.
121
 Indeed, multiple PrP
Sc
 types have been detected in CJD 
brains
134,135
 and mouse adaption of hamster prion strains by multiple passaging 
(Figure 1.2 C) provides further evidence for this theory.  
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Figure 1.2:  Prion strains, interspecies transmissibility and strain adaption 
(A) Prion strains (designated here as 1 and 2) differ in incubation periods (length 
of black arrows), neuropathology (affected brain areas indicated in red) and 
glycosylation pattern (black boxes, simplified illustration of a western blot). These 
strain characteristics are maintained over serial passages. (B) The strain 
properties may also retain after multiple passages in an intermediate species with 
a distinct PrP
C
 sequence. (C) Strain adaption: Mice were inoculated with hamster 
prions (here strain 263K) Over several passages the species barrier prevents 
effective transmission or at least clinical signs. During transmission an adaption of 
the prion strain can occur, but the properties of the strain might change.(modified 
from
121
)   
 
Additionally, distinct cattle prion isolates showed phenotypic characteristics similar 
to BSE if they were inoculated into transgene mice which overexpressed bovine 
PrP. In contrast, transmission into transgenic ovinized mice leaded to a different 
pathology.
136
 Thus, an abrogation of the species barrier seems to be associated with 
strain switching and therfore different phenotypes and prion strains may occur. 
Remarkably, the pathological and biochemical properties of vCJD could only be 
retained in humanized mice, which expressed PrP with a methionine a position 129, 
while a different phenotype was observed if methionine was substituted by valine. 
Moreover, after multiple passaging the transmission of BSE prions was 
inefficient.
137
 That genetic differences of the host species are not required for the 
occurrence of strain ‘mutations’ has also been shown.138,139 These experiments also 
clearly demonstrated that intra-species strain mutation might occur if the primary 
sequence of the host differs from that of the inoculated prion agent. Nevertheless, 
strain adaption in vivo necessitates two or more subpassages, presumably because 
several rounds of replication and conformational selection are necessary.
119,140
 
Then again, it was suggested that environmental influences might change prion 
strain properties. For example, it is likely that the thermostability of BSE prions is 
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caused by the selectional processes of offal recycling and its processing to carcass 
meal respectively.
121,141
 Evidence to support this notion comes from different 
thermodynamic stabilities of PrP
Sc
 sub-populations in thermostable TSE agents.
142
  
Additionally, prion strains were described as ‘quasi species’ which comprise readily 
interconverting conformers. This would imply that the adaption to exogenous 
constraints or the host environment is due to slightly changes of the PrP
Sc
 
conformation. In a particular environment this would lead to a coexistence of a 
major conformation and several variants (sub-strains, cp. Figure 1.3, p. 20).
119
 The 
theory is based on characteristic transmission properties of 22L prions under 
selective constraints in cell culture. PK1 cells were treated with mouse 22L prions 
in the presence of swainsonine. Swainsonine (swa) is a Golgi α-mannosidase II 
inhibitor which is capable to inhibit > 99% infection of PK1 cells by RML and 79A, 
but interestingly not by 22L prions. In contrast to brain-derived 22L prions, the 
replicated PK1[22L] prion samples failed to infect R33 cells. Moreover, the derived 
PK1[22L] prions became susceptibil for swa after several doublings. The inhibitor 
sensitivity increased over time up to a value of 30 to 40% per culture. However, the 
swa-sensitivity took a gradual course and was not observed directly after the first 
prion replication round. Hence, an influence of brain- or cell-components was 
excluded. The inhibitor resistance and the R33-competence could be recovered 
using low concentrations of the agent as a selective pressure. Once the inhibitor was 
omitted, resistance was lost again. Contrary to swa-sensitivity the build-up of swa-
resistance was faster. It was argued that the selective advantage of swa-sensitive 
prions in the absence of a selective pressure is relatively small compared to swa-
resistant prions, but is still high enough to enable this conformation to become 
dominant. If they were backpassaged into mouse brains all prion strains that were 
replicated in cell-culture regained the original 22L cell tropism. Indeed, similar 
osbservations were made before.
143,144
 The heterogenity of the 22L prion strain was 
also observed if cell cultures were biologically cloned by end-point dilution over 
several passages in the absence of swa. In order to explain the observations, 
evolutionary processes in prion propagation were proposed. It is noteworthy in this 
context, however, that real conformational differences between swa-resistant and 
swa-sensitive prions could not be shown.
140
 Nevertheless, strain shifts were also 
observed after cloning in vivo. When a non-cloned mouse strain was passaged into 
mice with slightly different Prnp sequences a new strain was derived while a cloned 
strain maintained its characteristics.
145
  But cloning does not consequently exclude 
the emergence of new transmission properties, as demonstrated with the prion strain 
139A.
146
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1.4 Protein misfolding  
Many neurodegenerative disorders, as, for instance prion diseases, Alzheimers 
disease or Parkinsons disease are associated with protein misfolding. In a self-
templated process which resembles seeded crystallization pathologic protein 
aggregates bind and structurally corrupt benign protein monomers.
2
 Thus, the terms 
‘protheopathy’ or ‘conformational disease’ might also be appropriate. The 
presumably self-perpetuating mechanism leads to seed amplification as the 
pathogenic aggregates sequester more and more monomers over time. Protein 
misfolding was firstly described for prion diseases and today it is widely accepted 
that the disease associated, pathological form of the prion protein, PrP
Sc
, is the main 
if not only part of a ‘proteinaceous infectious particle’ or ‘prion’.86,87,88,89,90 (cp. 1.2, 
p. 13 et seqq.) Thus, PrP
Sc
 can bee seen as the seed in mammalian prion diseases. 
There are clear indications that fibril formation is an intrinsic feature of 
polypeptides
147–150
: amyloids show a cross-β structure with β-strands perpendicular 
to the long axis of the fibril.
147,151,152
 Interestingly, precursor proteins, such as Aβ 
(Alzheimer), α-synuclein (Parkinson), Amlyin (diabetes type II), Insulin (diabetes 
type II) or β2-microglobulin (dialysis-related amyloidosis) have no sequence 
similarity and show structural diversity. Nevertheless, the structure of proteopathic 
seeds is not completely dertermined by the amino acid sequence. Thus, for instance, 
different amino acid side chain packing is possible in amyloid-like protein 
fibrils.
149,150
 Moreover, different Aβ-fibril morphologies were observed if fibril 
growth conditions were changed
153
 and different PrP
Sc
 conformations were shown 
to modulate the phenotypic characteristics of prion strains
132
. It was assumed for a 
long time that amlyoid formation is based on a mechanism in which primary 
(homogenous) nucleation is the rate-limiting factor.
154–161
 Primary nucleation is 
dependent on the concentration of monomeric peptides, but recent research in this 
field showed that amyloid formation seems not to fit in simple nucleated 
polymerization models.
162–167
 Thus, fibril formation has been attributed to the 
existence of secondary nucleation pathways, in which already formed fibrils 
catalyze the formation of new fibrils.
168–170
 Using the growth of actin as a model 
Wegner described the role of fragmentation in the context of secondary 
nucleation.
171,172
 Recent studies clearly demonstrated that spontaneous fragmen-
tation plays a role in fibrillar growth, albeit the spontaneous generation of nuclei is 
slow. Regarding the elongation of fibrils, at least for the amyloidogenic yeast prion 
protein, it could be shown that growth occurs by monomer addition.
173
 If 
fragmentation is used as a driving force growth curves show a sigmoidal shape and 
there is clear evidence that primary nucleation is negligible. In such a system the 
maximal growth rate is independent from the number of initial nuclei or the primary 
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nucleation rate which is contrary to the prevailing view in literature where growth 
rate and lag-phase are dependent of primary nucleation.
154,174
 Recent research not 
only addressed the influence of fibril fragmentation in amlyoid assembly, but also 
in cytotoxicity. Fragmented to different extent shorter amyloid β2m (β2-
microglobulin) fibrils, for example, showed higher seeding efficiency and higher 
ability for membrane disruption, while keeping the same structural properties as 
their longer counterparts.
175,176
 Lower infectivity and converting activity was also 
found for large native prion protein fibrils, whereas particels of 17-27 nm (300-
600 kDa) showed substantially higher values. Interestingly, in both cases (PrP and 
β2m) oligomers showed no or only low effect. This stands in contradiction to lots of 
findings which indicate that prefibrillar oligomers represent the toxic species in 
amyloid diseases.
177–181
 There is plausible reason to assume that specific molecular 
structures of proteopathic seeds and their stability have crucial influence on their 
propagation in vivo and only a limited number of specific seed conformations might 
go along with infectivity. For instance, prion replication in vivo does not 
consequently lead to the occurance of clinical signs
182–184
 and seeding effictivity of 
synthetic Aβ fibrils in vitro is not automatically accompanied with seeding activity 
in vivo.
185,186
 The folding of a polypeptide towards its native structure is often 
described by sequence-specific energy landscapes where local energy minima 
represent one or more thermodynamically stable protein conformations (Figure 
1.3).
147,187
 As announced earlier (1.3, p. 15 et seqq.), it was proposed that prion 
strains comprise seed populations of interconverting conformations (‘quasi 
species’).119 Hence, the structural interconversion of prion strains and ‘sub-strains’ 
was explained by relatively low activation energy barriers (Figure 1.3).
119,121
  
 
Figure 1.3:  Schematic energy landscape 
   (Left) The sequence specific energy landscape can be regarded as a three-
dimensional funnel where the surface represents the large number of potential 
conformations which change to reach local energy minima. Intra- and 
intermolecular contacts determine the outcome of the process. (modified from 
147
) 
(Right) Suggested energy landscape for prion strains and ‘sub-strais’: Strains are 
delimited by relatively high energy barriers, while sub-strains are represented by 
interconvertible confomers. Energy barriers between sub-strains can be overcome 
by selective pressure. (modified from
119,140
) 
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Amyloid formation in vitro is often realized under slightly denaturant or 
destabilizing conditions like low pH, high temperature or amino acid substitutions.  
For example the conversion of recombinant PrP in the QuIC (Quaking-induced 
conversion) assay (cp. 1.5, p. 23 et seqq.) takes place in the presence of SDS 
(sodium dodecyl sulfate). It is likely, that partial unfolding of the native state is 
favored and therefore, potentially, the conversion to an amyloidogenic state.
147,188
 
However, till date the exact structure of PrP
Sc
 as well as the underlying conversion 
mechanisms have not been solved. Nevertheless, three hypothesis can be usually 
found in the literature (Figure 1.4 A-C). In the template assisted (heterodimer) 
model the pathological isoform of PrP (PrP
Sc
) shows a high thermodynamic 
stability, but in the kinetic point of view its conversion is hard to accomplish.
94,189
 
The heterodimer model assumes the formation of an instable intermediate (PrP*). 
The equilibrium lies on the side of PrP
C
, but with support of a chaperone, for 
example, PrP* can form a heterodimer with PrP
Sc
. A spontaneous conversion of the 
heterodimer and a subsequent dissociation leads to two new templates and therefore 
exponential growth. It was argued that the the catalytic properties of PrP
Sc
 must be 
extremely high to generate full blown TSE symptoms within a lifespan.
190
 Indeed, 
there is a low incidence rate of spontaneous TSEs.
191
 Hence, Prusiner suggested a 
cooperative autocatalytic model (cooperative Prusiner model) in which a higher 
number of PrP
Sc
 molecules supports the conversion of PrP, while the catalytic effect 
of a single PrP
Sc
 molecule is kept low. It was also suggested that the critical step of 
the conversion reaction is the formation of an instable nucleus.
192,193
 In the so-called 
nucleation-polymerization model the equilibrium lies on the PrP
C
 site of the 
reaction until the unstable PrP
Sc
 oligomers form an aggregate with a decaying rate 
slower than the forming.
194,195
 These PrP
Sc
 aggregates bind to PrP
C
 and change the 
equilibrium. The assisted-nucleation model on the other hand suggested that PrP
Sc
 
cannot exist as a monomer. In this case, a cofactor might promote the binding and 
conversion of new PrP
C
 monomers, while fragmentation of the growing PrP
Sc
 
aggregates forms new nuclei.
190
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Figure 1.4:  Molecular mechanism models for the conversion of PrP
C
 to PrP
Sc
  
   (A) Template assisted (heterodimer) model; (B) Nucleation-polymerization model; 
(C) Assisted-nucleation model; (modified from
190
) 
It was argued that the structural conversion of PrP
C
 to its pathological conformer 
might be promoted by a cofactor (‘factor X’) or a chaperone (‘protein X’). The idea 
arose from transmission studies of human prions in mice: Transmission from human 
CJD prions to transgenic mice expressing human and mouse PrP failed. In contrast, 
the inoculation of chimeric mice leaded to disease symptoms. A subsequential 
transmission of human prions into humanized mice only successed if the mice were 
crossed into a PrPnull background. The observations were attributed to a mouse 
protein X, which interacts with murine PrP (mPrP), but does not bind to human PrP 
(hPrP).
196
 Moreover, the regions which were supposed to bind to protein X were 
mapped.
197
 The theory found support in cell-free conversion experiments. While 
highly purified PrP
C
 could not be converted in the presence of PrP
res
, an addition of 
cell proteins reconstituted the conversion ability.
198
 But not only proteins were 
discussed as potential partners in the misfolding process of PrP. Sequence-specific 
DNA binding to mPrP and the interaction between PrP
C
 and polyionic ligands, such 
as sulfated glycosaminoglycans, or anions in general have been shown early 
on.
199,200
 In vitro conversion experiments also indicated a key role of synthetic 
polyanions and RNA. Moreover, nucleic acid-promoted in vitro amplification 
seems to be strain-specific, especially if synthetic polyanions are used.
201
 However, 
attempts to structurally convert recombinant expressed PrP have already indicated 
that host cell proteins and cofactors might play a role, but are not obligatory.
202–205
 
Finally, latest investigations have proven that neither cofactors nor additional 
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proteins are necessary to replicate infectious prions in vitro.
90
 The mechanisms in 
vivo, however, stay unclear.  
1.5 In vitro conversion of the prion protein 
In order to reveal the underlying mechanisms of prion diseases it is of prime 
importance to investigate the conversion process of host PrP
C
 to its abnormal, 
unsoluble and partially protease resistant isoform PrP
Sc
. First attempts to propagate 
prions in vitro started in the lab of Stanley Prusiner. But neither simple mixing of 
chimeric cell lysates from mouse/syrian hamster (MHM2) PrP and purified PrP
27-30
 
nor the incubation of metabolically radiolabeled mPrP
C
 in prion infected cell 
cultures leaded to an in vitro or de novo formation of protease resistant PrP in 
detectable amounts. Furthermore, it was tried to structurally convert PrP
C
 which 
was synthesized in the presence of microsomal membranes from PrP
Sc
 infected 
sources, unfortunately without success.
206
 The first successful experiment of this 
type was performed in 1994
199
  In the presence of guanidinium as a denaturing 
component a conversion rate of 10-20% could be accomplished. Nevertheless, 
infectivity could not be shown
199
 and further experiments with cell-lysates 
followed.
198
 A main problem of these methods was the large excess of PrP
27-30 
which had to be used for a successful amplification of PrP
res
. However, the 
spontaneous conversion of PrP was believed to be relatively slow and the non-
satisfiying amplification yields necessitated a new method.
199
 In 2001, Saborio and 
coworkes used an ultrasonic approach to generate significant amounts of highly 
protease-resistant PrP
Sc
-like protein (PrP
res
) with a relative molecular mass of 
27,000-30,000 in its N-terminally truncated form (similar to PrP
27-30
).
5
 The method 
of in vitro replication of seed conformation was dedicated Protein Misfolding 
Cyclic Amplification (PMCA). It is based on periodic cycles of ultrasonic treatment 
which are believed to cause fribril fragmentation. The surface augment which 
attends this process is believed to apply more growth sites and therefore an 
increasing number of converting units (Figure 1.5).
5
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Figure 1.5:  In vitro conversion of prion particels in PMCA  
   Prions consist mostly if not completely of PrP
Sc
. PrP
Sc
 can act as a conformational 
template which structurally corrupts benign PrP
C
 monomers. Seed amplification in 
PMCA is based on alternating cycles of incubation and sonication in the presence 
of excess PrP
C
. Fibril fragmentation is believed to generate more growth sites and 
might therfore promote seed amplification. (adapted from
5
) 
In PMCA minor amounts of infectious tissue homogenate are mixed with a large 
excess of healthy brain homogenate
5,207,208
 or purified recombinant PrP
202
 (Figure 
1.6). Cellular PrP that was purified from brain homogenate can also be used.
209
  
 
Figure 1.6:  Cell-free in vitro conversion assays for prions 
   The prion amplification in vitro is usally based on a mixture of proteopathic seeds 
(e.g. scrapie brain homogenate or purified PrP
Sc
) and native PrP (e.g. brain tissue 
homogenate of healthy animals, purified PrP
C
 or recombinant PrP (recPrP)). In 
Protein Misfolding Cyclic Amplification (PMCA) seed amplification is predicated 
upon alternating cycles of ultrasonic bursts and incubation (indicated by the red 
flash). Besides replication of PrP
Sc
 PMCA was shown to amplify prion 
infectivity.
207
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Protease resistant PrP (PrP
res
) that was generated with PMCA was shown to further 
propagate protein misfolding (serial PMCA).
210
 By serial dilution of the original 
seed it could be demonstrated that PMCA is not only capable of amplifying PrP
Sc
, 
but also prion infectivity (Figure 1.6).
207
 Further development and automatization of 
the PMCA leaded to high effeciency, making the in vitro conversion much more 
senstive than the bioassay.
4,5,207–209,211–213
 Even though low amplification of PrP
Sc
 
can also be observed without sonication
5,112,214
, PMCA provides and efficient way 
for amplification of proteopathic seeds, especially when it is compared to cell-
culture based assays. For several years the PMCA has been used as a robust system 
for qualitatively analysis of prion containing samples of different origin, such as 
blood, brain or liver tissue.
212,215
 Various approaches were tried to optimize the 
yield and reproducibility of PMCA experiments. As stated before the binding of 
PrP
C
 to polyanions has been observed (cp. p. 22).
199,200
 Thus, nucleic acids have 
been tried to improve PMCA. Purified RNA, for instance, promotes the seed 
amplification in hamster tissue homogenates.
216
 Using native PrP
C
 and copurified 
lipids it was demonstrated that polyanions seem to be necessary to generate 
infectious prion particles.
203
 But also reduced pyridine nucleotides, such as NADPH 
(Nicotinamide adenine dinucleotide phosphate) seem to enhance the propagation of 
hamster-adapted PrP
Sc
.
217
 Aside from nucleic acids, synthetic polyanions like 
Poly(A) are also believed to interact with PrP
218
 and stimulate the amplification of 
PrP
Sc
.
219
 Apart from charged molecules also several detergents have been tested to 
increase the PrP
Sc
 amplification yield. For example, CHAPS (3-[(3-Cholamido-
propyl)dimethyl-ammonio]-1-propanesulfonate), CHAPSO (3-[(3-Cholamidopro-
pyl)dimethylammonio]-2-hydroxy-1-propanesulfonate), n-Decyl β-D-tiomaltoside 
and n-Undecyl β-D-tiomaltoside as well as NOG (N-oxalylglycine) were testet in 
PMCA. And in fact, the additon of NOG was found to be the most suitable to 
increase the reaction yield.
220 
 
Nevertheless, the use of special additives often causes just minor effects which are 
not seldom controversy: dextransulfates, especially potassium dextran sulfate, 
increase the reaction outcome in PMCA using bovine brain homogenates.
221
 In 
contrast, dextransulfate does not work out if RML is used as a seed.
216
 Thus, 
cofactors might be seed specific. Supporting evidence for this notion comes from 
the species-dependent effect of RNA in PMCA reactions.
216
 However, the role of 
nucleic acids in the misfolding mechanism of PrP has not been clarified yet. 
Literature indicates a promoting effect of RNA and poly(rA)
112,203,205
, but generation 
of infectious prions seems also to be possible in the absence of any cofactors
90
.  
Except for additives, the PrP
C
 concentration, as well as its constitution seem to 
influence the amplification reaction. While the replication of RML prions 
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necessitates unglycosylated PrP
C
 molecules, the diglycosylated form seems to be 
essential for the propagation of certain hamster prions (Sc237).
222
 Moreover, in 
substoichiometric levels unglycosylated hamster PrP
C
, but also certain PrP deletion 
variants can inhibit the conversion.
218,222
 Furthermore, a higher PrP
C
 content in the 
tissue homogenate enhances the conversion reaction
223
, but also PrP fragments have 
been shown to modulate the reaction outcome. Especially C-terminal and core 
region peptides increase the PrP
Sc
 amplification yield.
224
  
Due to the metal-binding capacity of PrP
225
 the effect of transition-metals was 
investigated in PMCA. In contrast to Cu or Fe the addition of manganese leads to 
different PrP
Sc
 glycosylation patterns. This is especially interesting, because 
increased manganese concentrations were found during scrapie transmission in 
hamsters.
226
  
Only a few attempts were focused on physical parameters like the influence of 
sonication times. The results indicated different optima for mouse adapted BSE and 
scrapie strains.
227
 Furthermore it was demonstrated that the PrP
Sc
 amplification 
yield is directly correlated with the amount of cycles in a PMCA experiment.
5,228,229
 
Technical improvements, however, have never been tested with one exception: the 
usage of Teflon™ beads seemed to increase the otherwise relatively low conversion 
rate in PMCA (PMCAb). Unfortunately, the phenomenon could not be explained in 
detail and better amplification yields were said to be caused by a better 
fragmentation. It was further argued that the method could also increase the 
accessibility of PrP
C
 or potential cofactors. Additionally, a cavitation mitigating 
effect was assumed if beads are used, leading to more specific conversion and less 
unspecific aggregation of PrP
C
.
230
  
Despite the yearslong utilization of PMCA in many laboratories the in vitro 
replication of uncharacterized prion seeds is often based on trial and error.
231
 There 
is also the fact that the generated samples were often not tested in vivo. Therefore, 
no statemant can be given wether or not the tested additives have a substantial effect 
on infectivity and ‘strain-ness’. Indeed, that is to that extent important, since in vitro 
generated prions are 10 to 100 times less infectious than native prions.
207
 
PMCA was also used to convert recombinant full-length hamster PrP and the 
generated PrP
res
 was shown to be different from spontaneous formed fibrils as well 
as native prions with respect to the IR spectra and the proteolytic sensitivity. 
Recombinant PMCA generates seed-specific particles of 11, 12, 13 and 17 kDa 
(after PK digest). Additionally, a spontaneous formation of PrP
res
 was observed. 
Interestingly, recPrP-PMCA necessitates the presence of SDS.
202
 The QuIC assay 
(quaking induced conversion) uses buffer conditions similar to those of 
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recPrP-PMCA. Instead of sonication – the driving force in PMCA – alternating 
cycles of shaking and incubation are taken out in a programmable laboratory shaker. 
In contrast to PMCA the QuIC assay shows higher sensitivity. Even femtogram 
amounts of PrP
res
, a concentration which lies below the lethal intracerebral dose, are 
detectable.
204
 Recent efforts leaded to high-throughput methods for estimating the 
relative amount of prions in samples of different origins.
232
 The quantification of 
prion samples is taken out by a thioflavin T based bioassay - the real-time QuIC 
(RT-QuIC). Its sensitivity is comparable to end-point quantification assays in 
animals, but less time consuming. Latest improvements made it possible to detect 
even ~2 ag/ml of proteinase K resistant particles.
233,234
 Nevertheless, the QuIC assay 
was not shown to amplify infectivity.  
Despite strong supporting evidence for the prion only hypothesis
126,132,199,203,207,235,236
 
(cp. 1.2, p. 13 et seqq.), the generation of a recombinant prion with bacterially 
expressed PrP would clearly dispel the last doubts. Indeed, PMCA could be used to 
amplify recombinant mammalian prions and their incidental infectivity in the 
presence of minor amounts of PrP
Sc
. Moreover, the absence of any additives seemed 
to invalidate the long discussed involvement of mammalian cofactors.
90
 Besides 
seeded amplification of infectious prions, also de novo generation of recombinant 
prions was demonstrated using PMCA.
205
  
1.6 The cellular isoform of the prion protein (PrP
C
) 
The prion protein (PrP) is a ubiquitously expressed 253 (in some species 252) 
amino acid long glycoprotein which is divided in two domains. It is encoded by a 
single-copy gene, designated Prnp in mice. Between mammalian species the amino 
acid sequence is highly conserved.
114,115
 It consists of a signal peptide (22 amino 
acids) for co-translational secreting into the endoplasmic reticulum (ER), five 
N-terminal copper-binding octapeptids and two glycosylation sites (cp. Figure 1.7).  
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Figure 1.7: The prion protein 
 (A) Illustration of the structure of the Mus musculus prion protein mPrP(121-230); 
The copper binding octapeptide repeats, glycosylation sites and the GPI-anchor are 
illustrated. (B) Sequence of mPrP(23-231) and mapping of secondary structure; (Top) 
Two basic stretches are shown in green, one hydrophobic stretch is shown in blue and 
the octapeptide repeats are indicated by grey boxes. (Bottom) The flexible disordered 
tail of mPrP is shown as a blue line while the globular domain is represented by a 
grey line. Sequence motifs are shown by colored boxes, α-helices are shown in red 
(α1, α2, α3), β-strands are symbolized by yellow boxes (β1, β2, β3). Specific sequence 
positions are indicated by numbers.(modified from
237,238
) 
 
Furthermore, one disulfide bridge can be found.
239
 PrP is located in lipid rafts – 
sphingolipid- and cholesterol-rich microdomains on the outer cell membrane.
240–242
 
Lipid rafts are detergent resistant and often contain cellular receptors, tyrosine 
kinases and GPI-anchored proteins.
243,244
 Indeed, PrP shows a 23 amino acid long 
C-terminal glycosylphosphatidylinositol (GPI) sequence. C- and N-terminal signal 
sequences get cut off in the ER and the Golgi apparatus during post translational 
modification. Species and strain dependent, three forms of PrP exist – mono-, di- 
and unglycosylated PrP.
245,246
 The oligosaccharides are from the high mannose-
type, endoglycosidase H sensitive and undergo a postmodification in the Golgi 
apparatus. While the N-terminal tail is structurally undefined, the C-terminal part is 
mainly globular and characterized by secondary structure elements. PrP
C
 is a 
soluble, mainly alpha-helical and a monomeric protein.
93,237,247
 Until now, the 
1 Introduction   29 
structures of recombinant PrP have been solved for many species including human 
PrP (hPrP)
248
, mouse PrP (mPrP)
237,238
, syrian hamster PrP (shPrP)
249
, bovine PrP 
(bPrP)
250
, as well as chicken, turtle and frog
251
.  
1.6.1 The function of PrPC 
The prion protein is mainly expressed in neural tissue, but can also be found in 
other mammalian organs.
252
 In spite of the efforts made, the physiological function 
of the prion protein still remains elusive: several studies revealed that PrP-deficient 
mice show no specific or lethal phenotype and no neural problems. Nevertheless, 
electrophysiological and circadian rhythm effects
101,253,254
, increased oxidative stress 
markers and higher sensitivity to neurological damage could be observed
255
. 
However, the symptomatology is strongly correlated with the type of the knock-out 
strategy. If the flanking regions like the splice acceptor site of the third exon are 
involved, ataxia and Purkinje cell loss can occur.
256
 It could be shown that cell 
degeneration and demyelisation of peripheral nerves lead to ataxia.
256–258
 Among 
other things exon skipping leads to an involvement of Prnd, which lies 16kb 
downstream of Prnp and encodes for Doppel (Dpl). Doppel gets overexpressed 
under control of the Prnp promotor
258,259
 and the onset of clinical signs is inversely 
correlated to the measured level of Doppel in the brain
258
. Doppel is similar to PrP, 
but lacks the N-terminal tail. Interestingly, the same effects could be reproduced in 
transgenic mice if PrP fragments were expressed which lacked the same sequence 
part as Dpl.
260
 Moreover, the negavie effect of a higher Dpl expression could be 
antogonized by an insertion of Prnp. Therefore, the cell loss can be attributed to the 
altered transcription of a neighboring gene and different models have been 
published to delineate the function of PrP as a neuroprotective antagonist to 
Doppel.
190,260
 The concentration of Doppel itself has no effect, neither on the TSE 
incubation time, spongiform degeneration nor PrP
Sc
 deposits.
261
 Interestingly, 
homozygous PrP-knockout mice are resistant to scrapie. They show no clinical 
signs for two years and neither propagation of prions in brain or spleen nor scrapie-
specific pathology within 57 weeks after inoculation could be detected.
235
 
Nevertheless, low levels of infectivity can be made out in PrP knock-out mice 
brains directly after intracerebral inoculation.
262,263
 However, a genotype with a 
single Prnp allele leaded to almost doubled incubation times, but similar levels of 
infectivity.
264
  
The octapeptide of PrP is able to bind copper ions (cp. Figure 1.7 A, p. 28).
265,266
 
Thus, PrP might act as a recycling receptor for the copper assimilation of the cell. 
Indeed, copper chelating agents can induce TSE-like pathology
267
, while an 
overexpression of PrP also leads to increased copper assimilation and superoxide-
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dismutase (SOD) activity. SODs prevent cells from superoxide toxicity.
268
 In 
addition, the slightly dismutase activity of PrP is inhibited in the presence of PrP
Sc
 
or  shorter PrP fragments. This might explain, at least in part, the neural damage 
caused by prion diseases.
269
 Usually PrP plies between plasma membrane and 
endocytotic compartiments.
270,271
 However, the internalization of PrP
C
 can be 
reversible stimulated by copper ions.
272
 Reduced copper concentration in brain 
tissue of PrP-knockout were observed, while increased copper levels were detected 
in serum samples.
265
 Unfortunately, these results could not be confirmed.
273
 
Nevertheless, a change in copper concentration, lower PrP-copper binding as well 
as a decreased antioxidant activity were observed in scrapie infected mice.
274,275
 
Similar observations were made for sCJD. The copper level in brain tissue of sCJD 
patients was found to be 50% less compared to healthy brain tissue samples.
276
 
Furthermore, copper increases the stability of β-sheets and promotes the shift from 
an alpha-helical to a β-sheet-rich isoform (PrPres).277  
It was also argued that PrP plays a role in signal transduction. For example, PrP
C
 
binds to Fyn – a member of the Src-family of tyrosine kinases.278 PrP also interacts 
with the prion interactor protein Pint1.
279
 Physiological relevance or effects, 
however, could not be shown. Because of its property to bind to Bcl-2 or BH2, the 
role of PrP in programmed cell death was also discussed. If it is overexpressed, 
Bcl-2 is able to decrease the susceptibility for apotosis of PrP
-/-
 neurons.
280
 Similar 
to PrP, the  sequence of BH2 (Bcl-2-homologe domain of Bcl-2-family) shows 
octarepeats. It binds to the proapoptotic protein Bax and inhibits apoptosis. 
Additionally, PrP
C
 itself inhibits Bax induced apoptosis.
281
  
 
 
 
2 Objectives 
The molecular structures of protepathic seeds, such as PrP
Sc
, and the underlying 
mechanisms of neurodegenerative disorders are still elusive. However, it is likely 
that specific seed conformations are not an exclusive feature of prion diseases. A 
better knowledge of the formation and stability of proteopathic seeds would provide 
a more accurate picture of the underlying principles in self-templated protein 
misfolding and could help to find new therapeutic approaches against 
neurodegenerative disorders. Unfortunately, neither seed populations, nor their 
hypothetical conformational interconversion have been observed directly. 
Nevertheless, it was demonstrated that amyloids share similar features. For instance, 
amyloid fibrils show a cross-β structure with β-strands perpendicular to their long 
axis.
147,151,152
 They are stabilized by hydrogen bonding and steric zippers. 
Interestingly, variable side-chain interactions of the constitutive protein monomers 
modulate the mechanical properties of the protein fibril.
282–287
  
Based on the assumption that differentially structured proteopathic seeds are 
selectable because of their specific fragmentability, we were thus looking for a new 
concept for the in vitro selection of individual seed populations from mixed starting 
populations.  
 
 
 
 
3 Materials and methods 
3.1 Materials 
3.1.1 Chemicals 
If not indicated otherwise the chemicals used in this PhD thesis were ordered from 
one of the following companys: Aldrich, Difco, Emerald Biostructures, Fluka, 
Gerbu, GIBCO BRL, Hampton Research, Merck, Millipore, Pharmacia, QIAGEN, 
Riedel-de Haën, Roche, Roth, Sigma und Stratagene. 
If not stated otherwise, all chemicals used were of ‘pro analysis’ (p.a.) grade. 
Water was deonized using a Milli-Q Plus Water Purification System (Millipore). 
Molecular-biological methods used in this work are adapted from standard collec-
tions of methods and protocols.
288–290
 These methods will not be explained in detail.  
Only variations of standard protocols have therefore been described below. 
3.1.2 Enzymes 
For the digestion of prion samples proteinase K (PK) from Merck was used. 
3.1.3 Size standards 
All SDS gels were performed using the SeeBlue® Plus2 Pre-Stained Standard from 
Invitrogen (3-188 kDa for the use with Invitrogen NuPAGE® MES gels). 
3.1.4 Additional agents and materials 
Specific agents are scheduled in Table 3-1. 
Table 3-1: Specifc agents 
Purpose Name Manufacturer 
Antibodies 
mAb 6H4 (primary) 
A4a (secondary) 
Prionics 
Protease inhibitor mix 
for SSA buffer 
Complete tablet  
EDTA-free 
Roche 
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Purpose Name Manufacturer 
SDS-PAGE 
20 x running buffer 
Invitrogen 
4 x LDS (Lithium dodecyl 
sulfate) sample buffer 
NuPAGE® Novex 
4-12% Bis-Tris Midi Gel  
SSA additive 
Dihexanoylphosphatidyl-
choline (DHPC) 
Avanti Polar Lipids 
Dimyristoylphosphatidylserine 
(DMPS) 
Western blot 
SuperSignal West Pico stable 
peroxide solution 
Thermo Scientific 
SuperSignal West Pico 
luminol enhancer solution 
Thermo Scientific 
Immobilon-P transfer 
membrane (PVDF 0.45 µm) 
Millipore 
Nitrocellulose transfer 
membrane 
Millipore 
3.1.5 Bicellar mixtures 
Bicellar mixtures were used to optimize PMCA reactions (cp. 3.6.1, p. 46 et seqq.). 
Bicelles are bilayered micelles and have originally been thought to be used in solid-
state NRM-studies. Used in an aqueous solution the edges of bilayer fragments are 
stabilized by certain detergents (Figure 3.1). Typical mixtures of dimyristoyl-
phosphatidylcholine (DMPC) with mild detergents like dihexanoylphosphatidyl-
choline (DHPC) or 3-(choalmi-dopropyl)-diemthylammonio-2-hydroxy-1-propane-
sulfonate (CHAPSO) are known to form bicelles. Thus, liquid crystalline like 
bilayer properties can be achieved with different detergent:lipid ratios (~1:2-1:5). 
The wide range of possible pH values and temperatures (~30-50°C) provides good 
accessibility for biochemical approaches. The capability to vary detergent 
concentrations without significant changes in bicelle properties makes this model 
system interesting for structural NMR-studies. By this means, observations can be 
verified using different detergent:lipid ratios and made observations can be ruled 
out to be due to detergent concentration. Additionally, bicelles can be aligned in 
magnetic fields and therefore present a good source for structural information. 
Several studies support the capability of DHPC-DMPC bicelles to mimic membrane 
bilayers and functional reconstitution of water-soluble protein activity.
291–298
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Figure 3.1: Model of a DHPC-DMPC bicelle 
   Molecules of dimyristoylphosphatidylcholine (DMPC) form distinct bilayers. The 
edges are stabilized by the detergent dihexanoylphosphatidylcholine (DHPC).  
Previous studies give support for the application of bicellar solution in PrP 
conversion experiments. So, cellular prion protein could be converted to a β-sheet-
rich form using equimolar mixtures of DHPC and dimyristoyl-phospholipids. 
Regarding the positively charge of PrP a small percentage of negatively charged 
dimyristoylphosphatidylserine (DMPS) was added to the solutions. However, de 
novo generated PrP
β
 and PrP
βf
 (PrP
β
 after detergent removal) failed to show 
infectivity in transgenic mice, which might be due to non-compatible 
conformational properties, the non-physiological pH-value of 5.0 during conversion 
or the lack of putative cofactors.
11,299
  
The bilayer thickness can be approximately calculated.
300
 The data needed for 
calculations, e.g. CMC (critical micelle concentration) and free DHPC content in 
bicelles has already been published.
301–303
 Specific volumes for calculations are 
taken from publications of Tanford and Tausk.
304,305
  With given specific volumes 
of 0.865 (DHPC) and 0.961 cm³ g
-1
 (DMPC) and an estimated value of 
0.961 cm³ g
-1
 for DMPS a 250 mM stock solution (10 x) was prepared. For bicelle 
mixtures a DMPC:DHPC ratio of 1 was used (q = [DMPC]/[DHPC] = 1; 
q
eff, 37°C
 = 1.25). The calculated bilayer thickness was 5.49 nm. 
The composition for 1 ml DMPC/DHPC resp. DMPC/DHPC/DMPS bicelle 
solutions is given below (Table 3.2). An appropriate intermixture of DHPC and 
bicelle solutions has been ensured by repeated freezing and thawing of the 
completed solutions. 
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Table 3.2:  Composition of bicellar compounds for PMCA or QuIC 
DHPC stock 
40% (w/v) 
      
DHPC 1 g 0.865 cm³    
ddH2O   1.635 cm³    
   2.5 cm³    
        
Bicelle stock 
(w/o DMPS) 
       
DMPC 250 mM 169.5 mg  162.8  µl 
(solid) 
DHPC 250  mM 113.4 mg  283.5 µl 
stock 
   282.9 mg  446.3 µl 
      553.7 µl 
buffer 
      1,000 µl 
        
Bicell stock 
(with 
DMPS) 
       
DMPC 250 mM 169.5 mg  162.8  µl 
(solid) 
DHPC 250  mM 113.4 mg  283.5 µl 
stock 
% DMPS 10  17.5 mg  16.9 µl 
(solid) 
   283.5 mg  446.8 µl 
      553.2 µl 
buffer 
      1,000 µl 
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3.1.6 Instruments 
A list of all instruments used during this thesis can be found in Table 3.3. 
Table 3.3:  Instruments 
Purpose Name Manufacturer 
Autoclave HAST 4-5-6 Zirbus 
Blot cell Trans blot® cell Bio-Rad 
Electrophoresis 
chamber (SDS-PAGE) 
XCell4 SurelockTM Midi-Cell Invtitrogen 
Gel documentation 
Electrophoresis 
Documentation 
Kodak 
Shear-generators 
(shear-generators for 
mechanical SSA) 
Silent crusher S  
(tool 3 F) 
Heidolph 
Incubator FunctionLine Heraeus 
pH-Meter MP 230 Mettler-Toledo 
Photometer Ultraspec 3,000 Pharmacia Biotech 
Mechanical SSA array 
Prototype 
(cp. 3.6, p. 46 et seqq.) 
Self-made 
Patent number 
EP2489427A1 and 
WO2012110570A1
306,307
 
Thermoshaker 
Thermomixer comfort 
with attachments for 1.5 ml 
reaction tubes or microtiter 
plates (MTP) 
Eppendorf 
Ultra sonic devices 
(PMCA) 
Misonix 4,000 with Cup Horn 
for PMCA 
Misonix 
PMCA setup 
Standard setup, as delivered 
by manufacturer 
(cp. 3.6.1, p. 46 et seqq.) 
Misonix 
Modified water supply and 
drain of standard setup as well 
as rotating sample holder and 
sample holder with Chladni-
figure-matched positions 
(cp. 3.6.1, p. 46 et seqq.) 
Self-made 
Acoustic SSA 
Prototype  
(cp. 3.7.1, p. 52 et seqq.) 
Self-made  
Patent number 
EP2489427A1 and 
WO2012110570A1
306,307
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Purpose Name Manufacturer 
Deionized water 
supplies 
Milli-Q Advantage A10 
Millipore 
Milli-Q Plus 
Centrifuges 
4K15C Sigma 
5417 Eppendorf 
Centrifuge rotors 
Aerosol-tight rotor for 
Eppendorf 5417 
Eppendorf 
Centrifuge rotors 
Swing-out rotor for Sigma 
4K15C for 50 ml, 15 ml 
reaction tubes and microtiter 
plates 
Sigma 
Dry bath FB15103 Fisher Scientific 
Luminometer LAS 3000 FujiFilm 
3.1.7 Prion strains 
Prion strains which have been used to seed in vitro PMCA and SSA reactions are 
listed below (Table 3.4). In vivo propagation (3.4, p. 42 et seqq.) in Syrian golden 
hamsters has been used for strain maintenance.  
Table 3.4:  Prion strains 
Prion strain Description Source of supply 
Sc237 Hamster PrP
Sc
 
Dr. Eckhard Flechsig and  
Prof. Dr. Michael Klein  
(Institute of Virology, University of 
Würzburg) 
263K Hamster PrP
Sc
 
Bruce W. Chesebro, M.D.  
(National Institutes of Allergy and 
Infectious Diseases, Hamilton) 
3.1.8 Buffer solutions 
Buffer solutions used in this thesis are listed below (Table 3-5). 
Table 3-5:  Buffer solutions 
Application Buffer Ingredients/manufacturer 
SDS gel 
electrophoresis 
NuPAGE® MES 
SDS Running 
Buffer 
20 x 
Invitrogen 
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Application Buffer Ingredients/manufacturer 
LDS sample 
buffer 4 x 
Invitrogen 
Proteolytic 
digest of prion 
samples 
 
PK Digestion 
buffer 
2 x 
2% (w/v) N-Lauroylsarcosin 
(Sarkosyl)/1 x PBS  
or 1 x PBS w/o Sarkosyl 
PK solution 
100 µg/ml proteinase K in 2 x 
PK Digestion buffer 
PMSF 
(phenylmethyl-
sulfonyl fluoride) 
solution 
20 mM PMSF in isopropanol 
General 
PBS 
10 x 
Na2HPO4*2H2O 100 mM 
NaH2PO4*H2O 100 mM 
NaCl 1,300 mM 
 
Brain 
homogenate 
Perfusion buffer 
EDTA 5 mM 
KCl 2.68 mM 
KH2PO4*H2O 1.76 mM 
Na2HPO4*2H2O 8.09 mM 
NaCl 137 mM 
pH 7.4 with HCl 
Filter with 0.2 µm pore size. 
* added from a 100 mM stock solution 
 
PMCA or  
Acoustic/ 
Mechanical 
SSA 
PBS-EDTA 
1 x 
NaCl 137 mM 
KCl 2.68 mM 
Na2HPO4*2H2O 8.09 mM 
KH2PO4*H2O 1.76 mM 
EDTA* 1 mM 
pH 7.4 with HCl 
Filter with 0.2 µm pore size. 
* added from a 100 mM stock solution 
 
Conversion buffer 
PBS-EDTA 1 x 19.2 ml 
5 M NaCl* 600 µl 
Triton X-100* 200 µl 
Add one Complete protease inhibitor pill. 
((Roche pillppill right before use. * Add fresh before use. 
 
 
**   = 150     mM 
*** = 1%  (v/v) 
 
Western blot 
TBST 
20 x 
Tris base 500 mM 
KCl 60 mM 
NaCl 2,800 mM 
Tween 20 1 % (v/v) 
 
Transfer buffer 
10 x 
Tris base 200 mM 
Glycine 1,500 mM 
10% (w/v) SDS 1 ml/l 
Methanol 20 % (v/v) 
 
Blocking solution 
in 1 x TBST 
Milk powder 5 % (w/v) 
Goat Serum 1 % (v/v) 
 
Washing solution 
in 1 x TBST 
Milk powder 1 % (w/v) 
 
Rinsing solution 1 x TBST 
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Application Buffer Ingredients/manufacturer 
Primary antibody mAb 6H4 1:5,000 in washing solution 
 
Secondary 
antibody 
A4a 1:2,000 in washing solution 
 
3.2 Protein analytical methods 
3.2.1 SDS-Polyacrylamid-gel electrophoresis (SDS-PAGE) 
SDS gels of digested prion and recombinant PrP samples were performed using the 
NuPAGE® SDS-PAGE Gel System (XCell4 Surelock
TM
 Midi-Cell, Invitrogen) and 
NuPAGE® Novex 4-12% Bis-Tris Midi Gels. All gel runs were carried out using 
1 x LDS (Lithium dodecyl sulfate) sample buffer (working concentration 1 x, 
Invitrogen) and 1 x running buffer (from a 20 x stock solution , Invitrogen). For 
electrophoretic separation 200 V for 45 min were applied. Completed gels were 
used for subsequential western blot analysis (cp. 3.2.2). 
3.2.2 Prion sample proteinase K digest and western blotting 
Frozen prion samples were thawed up and short spun at 4°C. By pipetting the pellet 
was resuspended and 20 or 30 µl were transferred in a 1.5 ml screw cap reaction 
tube and stored on ice. After finishing the aliquots, step-by-step, the same volume 
of ice cold PK solution was added to the prion samples, to give a final concentration 
of 50 µg per ml. Once the PK was added, the mixture was vortexed immediately for 
three seconds and digested on a Thermoshaker (37°C, 750 rpm). Following a short 
spin for five seconds and an additional vortex step all samples were digested for one 
hour.  
To stop the digest, exactly after one hour, 1/3 volume of 4 x LDL sample buffer was 
added to the digestion mixture. The sample was vortexed and immediately 
incubated at 96°C (750 rpm) for more than 10 min. After boiling, the samples were 
centrifuged for ten seconds at 25,000 x g (4°C).  
Thereafter, samples were used for SDS-PAGE analysis (cp. 3.2.1). On the brink of 
transferring to the gel, samples were shortly mixed. Subsequently, a western blot 
using a nitrocellulose or PVDF membrane (activated with methanol) was performed 
using the Bio-Rad Trans blot® cell system at 65 V for 1.5 hours. The protocol for 
blot development is given below (Table 3-6).  
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In an alternative protocol higher numbers of prion samples were digested using 96-
well PCR plates and compatible Eppendorf Thermoshaker attachments. This 
method was especially applied for numerous samples of SSA reactions (3.6, p. 46 et 
seqq.):  
Shock-frozen samples of SSA reactions were thawed for 10 min at 22°C using 
Thermoshakers with a rotation speed of 1,000 rpm. Kept at 4°C and after short 
mixing with a 1,000 µl pipette volumes of 10 µl were successively transferred to a 
pre-cooled microtiter plate. The plate was sealed with translucent adhesive foil and 
centrifuged for one minute at 500 x g. Using an eight-channel pipette 20 µl of PK 
solution were added and samples were mixed by pipetting. Again the microtiter 
plate was covered with foil. To ensure sealing of the foil and to avoid aerosol 
leakage during the digest a strong pressing on is highly recommended. The plate 
was transferred to a prewarmed Thermoshaker and samples were digested for one 
hour at 37°C and 1,000 rpm. Directly after five minutes the incubation was 
interrupted for a short centrifugation step (500 x g for 1 min at RT) followed by a 
continuation of the digest for the remaining 55 minutes. Following this, the plate 
was stored on ice for 5 min.  
Under usage of a multichannel pipette 1 µl of PMSF (phenylmethylsulfonyl 
fluoride) stock solution was added to each well to inhibit protease acitvitiy. The 
protease inhibitor was intermixed with the digestion mix by stirring at 1,400 rpm for 
1 min using the Thermoshaker (precooled to RT). Once again the plate was 
incubated on ice for 5 min, followed by the addition of 4 x LDS sample buffer (7 µl 
per well) with aid of the multichannel pipette. For the boiling step that followed 
(96°C ≥ 10 min in a dry bath) the plate had to be sealed with PCR lid stripes instead 
of adhesive foil, which showed up not to be heat resistant. Before boiling the plate 
was thoroughly shaken to ensure good intermixture (Thermoshaker, 1,400 rpm for 1 
min at RT). Boiled samples were stored on ice until further use for SDS-PAGE (cp. 
3.2.1, p. 39). Completed gels were transferred to PVDF (activated by methanol) or 
nitrocellulose membranes using a methanolic transfer buffer and the Trans blot® 
cell system (Bio-Rad). For transfer 65 V for 1.5 hours were applied. Development 
of the blot followed the steps which are given in Table 3-6.  
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Table 3-6: Blot development 
Step 
Time 
[min] 
Temp. 
[°C] 
Solution 
Vol. 
[ml] 
Blocking 45 (or o/n) RT (4°C) Blocking solution 40 
Rinse 0.5 RT Rinsing solution ~40 
Washing 3 x 10 RT Washing solution 40 
1
st
 antibody 45 RT 
mAb 6H4 goat-anti-mouse PrP, 
1:5,000 
10 
Rinse 0.5 RT Rinsing solution ~40 
Washing 3 x 10 RT Washing solution 40 
2
nd
 antibody 45-60 RT A4a, 1:2,000 10 
Rinse 0.5 RT Rinsing solution 40 
Washing 3 x 10 RT Washing solution 40 
Rinse 0.5 RT Rinsing solution 40 
Detection  RT ECL Western Pico 2 + 2
1
 
3.2.3 Quantification of prion samples by western blotting 
Developed western blots were submerged with ECL Western Pico solution (2 ml 
peroxide solution + 2 ml enhancer for a standard blot size corresponding to a 26 
lane the NuPAGE® MES Bis-Tris Midi-gel) and analyzed using the LAS 3,000 
system (FujiFilm). Sensitivity was set to “super” and plate position 2 was chosen. 
Shots were successively taken after exposure times of 
1
/8; ¼; ½; 1; 2; 4; 8; 10; 30; 
60; 120 and 240 seconds. Quantification was performed using the Aida Image 
Analyzer software (Raytest).  
3.3 Safety precautions for work with scrapie prions 
The performed work was agreeable to the order 603 of the Health and Safety 
Executive  (Federal institute of industrial safety and industrial medicine; Ger.: 
Bundesanstalt für Arbeitssicherheit und Arbeitsmedizin). All decontamination and 
disinfection protocols have been adapted from several publications
20,62,64,66,67,308
 and 
are listed in Table 3.7. 
 
                                              
 
1
 A standard blot made from a 26 lane the NuPAGE® MES Bis-Tris Midi-gel was developed using 2 ml 
peroxide solution + 2 ml enhancer solution per membrane 
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Table 3.7:  Decontamination protocols 
Type of object  Decontamination  
Surface (e.g. lab furnitures), 
Plastic ware (e.g. dishes, beakers) 
1 M NaOH (≥ 1 h),  
general cleaning with 1% (v/v) LpH
TM
se 
Solid waste (e.g. gloves, tissue paper)  
and animal cages 
autoclaved at 134°C (2 bar) for one hour or at 
143°C for 30 minutes 
Body parts of prion inoculated animals 
incubated in 1 M NaOH/0.5% (w/v) SDS (≥ 1 h) 
and autoclaved at 121°C for one hour in this 
solution 
Metal-objects and glassware 
Due to higher resistance of prions on metal 
surfaces and glassware
309
 objects were treated 
with 1 M NaOH/0.5% (w/v) SDS (≥ 1 h), rinsed 
with water, followed by a decontamination in 
5 M GITC (≥ 1 h). 
Shear-generators (dispersion tools) 
Disassembling and decontamination in 
1 M NaOH/0.5% (w/v) SDS (submerged, ≥ 1 h) 
PTFE (polytetrafluoroethylene) bearings and 
O-rings were discarded, rest was thoroughly 
washed with deionized water 
decontamination in  5 M GITC (≥ 1 h)  
all parts were thoroughly washed with deionized 
water, only metal parts were autoclaved at 
121°C for 30 min in 1 M NaOH/0.5% (w/v) SDS 
parts were again rinsed with water and incubated 
in high concentrated formic acid (≥ 1 h) 
3.4 In vivo prion propagation 
Strain maintenance of prion strains and the provision of sufficient amounts of prion 
isolates for in vitro experiments were ensured by in vivo passaging.  
For that purpose  six to eight weeks old, male, healthy wild-type Syrian golden 
hamsters (Mesocricetus auratus; Harlan or Charles River) were anesthetized and 
injected intracranially into the right hemisphere with 30 µl of 1% (w/v) inoculum in 
filter sterilized PBS (prion strains 263K or Sc237). After strain-specific latency 
periods of 90-100 days the animals started to show clinical signs like ataxia, 
disinterest and drowsy behavior. If adequate and sufficient dietary intake could not 
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be ensured anymore due to illness, badly affected animals were sacrificed for brain 
removal (cp. 3.5, p. 44 et seqq.). 
The animals were anesthetized using subcutaneous injection of Ketamin and 
Medetomindin. Antagonization was performed using Atipamezol. Concentrations 
and dosage are listed in Table 3.8. Intracerebral injection was performed with help 
of Dr. Verena Haist (University of Veterinary Medicine Hannover, Institute of 
pathology). A tuberculin syringe was used. Injection depth and the necessary 
cannula size to drill through the skull plate had been investigated by tests with dead 
animals. Reproducibility of injection depth was ensured by usage of self-made 
spacers (built from the cannula cap). After injection of the homogenate the needle 
was not directly removed to avoid unwanted reflux and therefore spread of 
contaminated liquid. To stabilize the cardiovascular system, inoculated hamsters 
were bedded on warmed gel pads.  
Table 3.8:  Anesthetization and antagonization of Syrian golden hamsters 
Anesthetization working solution 
   Final concentration 
Ketamin  
(10%, WDT, Garbsen, Germany) 
0.6 ml 12 mg/ml 
Medetomindin  
(Domitor, Pfizer, Karlsruhe, 
Germany) 
0.1 ml 0.02 mg/ml 
Physiological saline solution 4.3 ml  
Total 5   ml  
    
Dosage  
0.8 ml working solution /100 g body weight 
s.c.  
 
 
Equal to dosage  
Ketamin 96 mg/k
g 
body weight 
Medetomindin 0.16 mg/k
g 
body weight 
 
Depending on the animal behaviour it can be necessary to inject additional 0.1-
0.2 ml of the working solution after 20-30 min. 
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Antagonization working solution 
Atipamezol 
(Antisedan, Pfizer, Karlsruhe, 
Germany) 
0.1 ml  
Physiological saline solution 4.9 ml  
Total 5 ml  
    
Dosage  
Use 1/3 to 1/2 of the initial anesthesia injection 
volume s.c. approx. 1-1.5 hours after anesthesia.  
 
Equal to dosage  
Atipamezol 0.3-0.4 
mg/k
g body weight  
3.5 Brain tissue homogenate 
Brains of healthy, six to eight weeks old, male Syrian Golden hamsters 
(Mesocricetus auratus; Harlan or Charles River) were used to prepare normal brain 
homogenate (NBH). Since the concentration of PrP
C
 is relatively high in neural 
tissue
252,310,311
, NBH was used as a substrate for in vitro PrP conversion experi-
ments (cp. 1.5, p. 23 et seqq.), such as PMCA and SSA. 
Euthanasia, perfusion of the circulation system as well as the organ harvesting of 
healthy hamster brains and the later tissue homogenization were performed on a 
prion free workbench. The animals were asphyxiated with carbon dioxide. The 
abdominal wall was opened with a small incission, the conjunctive tissue was 
disjointed using surgical scissors. Following three cuts were performed: two lateral 
relief cuts and one ventral cut from the xiphoid of the sternum up to the throat. Two 
additional relief cuts towards the paws were performed after dissecting the 
conjunctive tissue of the thorax. The hepatic lobes were set aside. In the next step 
the diaphragm was cut semicircular, following the curvature of the thorax. With 
lateral cuts the costal arches were severed and the thorax was opened. 
Then, a 20 ml-disposable syringe was filled with perfusion buffer (RT). A 
21 G-cannula was used for horizontal injection into the left ventricle. Once the 
cannula had been injected, the right atrium was cut in. The perfusion was performed 
using two times 20 ml with a constant flow rate of approximately 10 ml/min. After 
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refilling the syringe, the same injection point was used again to avoid buffer 
leakage.  
A successful perfusion of the brain is indicated by a rapid discoloration of the liver 
and the fine intestine blood vessels.  
Afterwards, the animal was decapitated between the skull base and the first cervical. 
Hampering muscle tissue was removed. With small scissors a horizontal cut below 
the brain to the ears was done on both sides. A last vertical cut was done along the 
cranial suture.  
Ideally, the skull plate opens up by itself. The perfused brain is of yellowish white 
color and shows no reddish discoloration.  
Nasal nerves and stem brain were removed and the brain was washed with about ten 
milliliters of perfusion buffer. Rinsed brains were flash frozen in liquid nitrogen and 
stored at -80°C until later use. The time period between the animal’s death and the 
shock freezing of the brain averaged out to 20 min. 
Brain tissue homogenate of scrapie affected hamsters was used to seed in vitro PrP 
conversion reactions. When pronounced clinical signs of prion disease became 
evident in the hamsters, the brains were harvested (cp. 3.4, p. 42). Contrary to 
healthy animals, the procedure was carried out on a prion working bench under 
certain biological safety aspects: Instead of protective goggles a safety ventail was 
used and the arms were covered with protective sleeves. Furthermore, the procedure 
was performed in a plastic dish. Additionally, the surrounding surfaces were 
covered with aluminium foil.  
Contrary to the preparation of substrate (NBH) for in vitro prion amplification and 
the preparation of seed (scrapie brain homogenate, ScBH) does not necessarily 
require perfused brains. Anyway, the absence of blood might positively influence 
the reaction.  
Materials and body parts were decontaminated as stated in Table 3.7 (p. 42). 
For the preparation of brain homogenate frozen hamster brains were taken out of the 
storage freezer and immediately covered with ice. The brains were covered with the 
necessary volume of freshly prepared ice cold conversion buffer to finally create a 
10% (w/v) brain homogenate. Filled into the glass tube of a pre-cooled dounce 
homogenizer, the organs were squashed by rotation of the pistil at the bottom.  
Followed by twenty strokes the tissue was finally crushed. Bubble formation was 
avoided. Afterwards, aliquots of about four milliliter were centrifuged in pre-cooled 
46 3 Materials and methods 
15 ml-reaction tubes for 2 min, 2,000 x g at 4°C. The supernatants were pooled. In 
contrast to NBH the homogenization procedure of scrapie prion brains was 
performed using sterile 10 ml-disposable syringes (18 G and 21 G-cannula, ten 
strokes).  
After the homogenization procedure the NBH should have a yellowish white color. 
A reddish color indicates residual blood in the tissue. In this case, the homogenate 
was discarded. Freshly prepared NBH was stored on ice and used within one hour. 
Scrapie brain homogenate was aliquoted, flash frozen and stored at –80°C until 
further use.  
3.6 PrP
Sc
 amplification by ultrasonic processing 
3.6.1 Protein Misfolding Cyclic Amplification (PMCA) 
As stated earlier the PMCA represents a powerful method for generating significant 
amounts of infectious prions in vitro (cp. 1.5, p. 23 et seqq.). Optimiziation 
strategies to amplify uncharacterized prion isolates, however, are based on a trial 
and error.
231
 Prior to acoustic SSA we tested the standard PMCA approach (cp. 
3.7.1, p. 52 et seqq.). Observations that were made on the overall amplification 
efficiency directly leaded to improvements of the standard PMCA setup
207
 as well 
as the development of the acoustic SSA (cp. 3.7.1, p. 52 et seqq.). The standard 
ultrasonication setup – as purchased from Misonix (Misonix 4,000) consists of a 
control device, an ultrasonic generator and a corresponding Cup Horn sonotrode 
with an attachable water bath. The standard sample holder is a floating plate that 
can be used for prion amplification reactions in thin-walled PCR tubes (Figure 
3.3 A). An output frequency of 20 kHz is stated for the device. Regarding the 
propagation velocity of sonic waves in water the wave length is calculated as 
follows: 
 𝜆 =
𝑐
𝑓
=
1,45 𝑘𝑚/𝑠
20,000 𝐻𝑧
=
1,45 𝑘𝑚/𝑠
20,000
⋅
1
𝑠
= 7,25 𝑐𝑚 (3.1) 
𝜆 represents the wavelenght. 
𝑐 is the propagation velocity of sonic waves in a particular elastic medium. 
𝑓 is the frequency. 
 
Water inlet and outlet of the system were connected to a customary temperature-
controlled water bath with an implemented pump. To guarantee a constant water fill 
level in the Cup Horn water bath the tube lengths and dimensions as well as the 
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height differences between pump and Cup Horn were never changed. Bacteria 
growth was avoided by regularly renewel of the water. Thus, also metal particles 
that were detached from the sonotrode surface by cavitational damage (cp. Figure 
3.2) were removed. The wear and tear of the sound emitter, which mainly consists 
of aluminium (AlMgSi, > 99% aluminium), necessitates a frequent exchange. On 
that purpose, sonotrode replicas were ordered from a local milling company.  
The standard stetup from Misonix was used for initial experiments using the 
hamster prion strain Sc237. Different starting seed dilutions were tested. Therefore, 
a 10% (w/v) ScBH was diluted 1:10, 1:20, 1:50, 1:100, 1:200 and 1:400 into a 
10% (w/v) NBH. Aliquots of 100 µl were processed at a power level of 90% for 
40 seconds every 60 minutes (24 cycles, 37°C). Additionally, the seeding capability 
of the generated reactions product was tested in serial PMCA. On that purpose, the 
processed reaction mixture was diluted 1:10 into new NBH and again processed for 
40 seconds every 60 minutes (24 cycles). In a second experiment the influence of 
sample positioning was surveyed. A 10% (w/v) Sc237BH was diluted 1:20 into a 
10% (w/v) NBH. Aliquots of 100 µl were processed at a power level of 90% for 40 
seconds every 60 minutes (24 cycles, 37°C, sonotrode replica I).  
Bicellar mixtures are known to show substantial effect on the conversion of 
recombinant PrP to a β-sheet-rich isoform.11,299 As announced earlier DHPC-DMPC 
bicelles showed the potential to act as membrane bilayers (3.1.5, p. 33).
291–298
 The 
prion protein is GPI-anchored. Thus, it is likely that the in vivo conversion of PrP
C
 
takes place at certain membrane sites with or without support of other membrane-
associated molecules. The C-terminal domain of PrP
C
 is largely positively charged. 
Therfore, negatively charged bicelles (charged by addition of phosphoserine) were 
thought to show the strongest effects. Thus, the effect of lipid and bicelle addition 
was surveyed in PMCA. Therefore, a 10% (w/v) Sc237BH was diluted 1:20 into a 
10% (w/v) NBH. The reaction mixture contained DHPC/DMPC bicelles (final 
concentration 25 mM (0.5 or 10% Phosphoserine), cp. 3.1.5, p. 33) or DHPC alone 
(12.5, 25 or 50 mM). Aliquots of 200 µl were processed at a power level of 90% for 
40 seconds every 60 minutes (24 cycles, 37°C, sonotrode replica I). 
In order to further investigate if the PrP
res
 amplification is better near to the center 
of the sonotrode or at the rim, a centered sample holder with a helical positioning of 
the samples was used. Floating on the water surface this device could rotate around 
an axis perpendicular to the middle of the sonotrode and was driven by the water 
flow of the system (Figure 3.3 B). A 10% (w/v) Sc237BH was diluted 1:20 into a 
10% (w/v) NBH. The amplification of PrP
res
 was surveyed in the presence and 
absence of DHPC/DMPC bicelles (final concentration 25 mM (no Phosphoserine), 
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cp. 3.1.5, p. 33). Aliquots of 100 µl were processed at a power level of 90% for 
40 seconds every 60 minutes (48 cycles, 37°C, sonotrode replica I). 
To investigate the soundwave emission of the sonotrode, we took a closer look at 
the shape of the cavitation damage pattern on the Cup Horn surface (Figure 3.2). 
Three recreated Cup Horns showed individual patterns of irregular shape (Figure 
3.5, p. 54) which resemble the geometry of the underlying harmonic surface 
oscillation function.  
 
Figure 3.2: Cavitation effect in local pressure minima due to oscillation of the sonotrode 
   Following the law of Bernoulli the static pressure of a liquid gets lower with its 
increasing velocity. If the static pressure deceeds the vapor pressure of a liquid, 
steam bubbles can occur. Moved by the flowing liquid these bubbles reach areas of 
higher pressure. The rapidly increasing static pressure leads to a sudden 
condensation at the bubble walls. Implosively water streams back and an extreme 
temperature and pressure boost is the consequence. Cavitation bubbles are 
relatively big (up to 150 µm) and occuring pressure and temperature gradients can 
reach up to 500 bar and 5200 K. Sticked to a surface, these cavitation bubbles 
form a microjet which leads to known damages on pump parts, ship’s propellers 
and also sonotrodes. Cavitation effects occur in a low frequency range from 20 to 
100 kHz.  
With the purpose to understand the influence of the oscillation behavior on the 
amplification of PrP
res
 we considered to use fixed sample positions. Thus, a new 
sample holder was developed. The position of the reaction vials were matched to 
the estimated anti-nodes of replica I (Figure 3.3 C and Figure 3.4). Additionally, the 
water bath was modified to ensure a better water circulation and therefore a better 
temperature control (cp. Figure 3.4). This was achieved by four flexible tubes 
attached to four T-piece adapters, which were fixed at the outer plastic ring of the 
Cup Horn water bath. All tubes were connected to the water inlet of the pump and 
rendered the existing outlet tube unnecessary. This, in turn, from then on worked as 
a second water inlet. By usage of T-piece adapters the newly connected tubes were 
upwardly opened and trapped air bubbles were avoided. The height difference of 
pump and Cup Horn water bath, flow rate, as well as tube lengths and arrangements 
were checked prior to each experiment to allow a constant water level above the 
Cup Horn and therefore a reproducible oscillation behavior of the sonotrode. The 
sample holder was always completely submerged. 
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Figure 3.3: Different sample holders for PMCA 
   (A) Standard floating sample holder (Misonix 4,000 PMCA setup); (B) Centered 
sample holder to analyse the radius dependence of sonotrode in PMCA reactions; 
The device could rotate around an axis perpendicular to the middle of the 
sonotrode. It was propelled by the water circulation. (C) Fixed sample positions; 
The positions of the reaction vials were matched to the observed vibrational 
pattern of replica I. Eight screws at the rim of the sample holder could be used to 
adjust the height. The screws were standing on the plastic rim of the water bath 
with no direct contact to the sonotrode. 
The amplification of the hamster prion isolates 263K and Sc237 was determined at 
multiple heights (0.5, 3, 5, 7 and 9 mm) above the sonotrode surface. A 
10% (w/v) ScBH was diluted 1:20 into a 10% (w/v) NBH. Aliquots of 200 µl were 
processed at a power level of 90% for 60 seconds every 10 minutes (24 cycles, 
37°C, sonotrode replica I). 
Reaction mix and preparation steps for PMCA 
Frozen scrapie brain homogenate was thawed and mixed with freshly prepared 
NBH (cp. 3.5, p. 44 et seqq.) by pipetting. If not mentioned otherwise a 5% (v/v) 
mixture of 10% (w/v) ScBH in 10% (w/v) NBH was used for conversion reactions. 
Long storage as well as freezing of the homogenates before usage was avoided. 
Thin-wall PCR-tubes were filled with the reaction mix and were flash frozen in 
liquid nitrogen for later use. Reaction volumes varied and are given for the 
particular experiments (cp. Table A.1, p. 91). Before using frozen samples were 
thawed at 37°C for 10 min. If necessary, sample tubes were mildly spinned to avoid 
deposition of droplets in the lids. However, pellet forming was avoided.  
Another fact which has to be stated is that freshly produced brain homogenate is 
viscous. Included SDS and Triton X-100 act as frothing agents. Thus, to exclude 
later differences in amplifcation due to different processing, trapped air bubbles and 
froth were strictly avoided. Reaction tubes with droplets in the cap, spurted from the 
homogenate at the bottom, were also not rarity in standard reactions. Of course this 
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effect entailed incomplete processing and could be avoided if reaction tubes were 
mounted as described in Figure 3.7 A. Prior to each experiment the samples were 
exposed to one sonic burst (power level and length were set as the process steps for 
the particular experiment) to redissolve settled material. 
A list of all performed PMCA experiments is given in Table A.1 (p. 91) 
 
Figure 3.4: Fixed sample positions in PMCA 
   (A) Water bath modification in PMCA. Four flexible tubes were attached to four T-
piece adapters, which were fixed at the outer plastic ring of the Cup Horn water 
bath (Misonix). All tubes were connected to the water inlet of the pump and 
rendered the existing outlet tube unnecessary. This, in turn, from then on worked as 
a second water inlet. By usage of T-piece adapters the newly connected tubes were 
upwardly opened and trapped air bubbles were avoided. The modifications of the 
water drainage avoided unnecessary sample heating. Additionally, a Cup Horn 
specific sample holder was built. The positions were matched to the observed 
vibrational pattern of a recreated sonotrode. While the reaction vial position could 
be exactly reproduced in the horizontal plane, eight screws also allwed to control 
the height. Vertical postioning was accurate to half a millimeter. (B) Wrong color 
image of a recreated sonotrode (replica I, cp. Figure 3.5, p. 54); Vibration nodes 
are black (top). The corresponding sample holder is shown in top view (bottom). 
Estimated optimal positions are indicated in green (top and bottom). A cross-
sectional view is exemplary shown for position six. All technical modifications of 
the sonotrode setup were planned and realized by Dr. Thorsten Lührs (HZI). The 
system is registered under the patent number EP2489427A1 and 
WO2012110570A1.
306,307
3.7 Selective Shearing Amplification (SSA) 
Today it is widely accepted that phenotypically distinguishable prion strains are 
largely determined by prion seed conformations (cp. 1.3, p. 15 et seqq.).
312
 Never-
theless, the molecular properties of self-propagating proteopathic seeds still remain 
unclear. It is, however, well known that the specific seeding activities of protein 
seeds depend on the particle size.
177
 Thus, fibril fragmentation influences fibril 
formation processes.
174,313
 Indeed, these facts were supported by experiments of 
Silveira and coworkers which demonstrated that the specific infectivity of the 
hamster prion strain 263K strongly depends on the size of the prion particles.
177
 It is 
possible that a uniform seed population might comprise a distribution of size-
separable particles of the same conformation, which differ in their activity. 
Although the molecular structures of protein seeds are unclear, it was demonstrated 
that amyloids share similar features. For instance, amyloid fibrils show a cross-β 
structure with β-strands perpendicular to their long axis.147,151,152 They are stabilized 
by hydrogen bonding and steric zippers. Interestingly, variable side-chain 
interactions of the constitutive protein monomers modulate the mechanical 
properties of the protein fibril.
282–287
 We therefore expected that differentially 
structured proteopathic seeds are selectable because of their specific fragmen-
tability. Kinetic models provided by Knowles and coworkers indicated that the 
number of initial nuclei resp. the primary nuclation rate do not influence the 
maximum growth rate (Vmax) in polymerization (cp. 1.4, p. 19 et seqq.). Moreover, 
fragmentation clearly promotes in vitro polymerization of fibrils and toggles growth 
rate and lag time. In the particular case of seeded growth primary nucleation 
processes can be neglected.
174,314
 Thus, fibrillar growth is determined by seed 
elongation, monomer dissociation and seed fragmentation. In the case of induced 
fragmentation, spontenaous fragmentation processes can also be neglected. 
We developed a new concept for the in vitro selection of individual seed 
populations which is based on shear stress induced seed fragmentation. Shear forces 
act parallel to particle cross-sections and critical shear leads to log-normal particle 
size distributions
315
 which evince an explicit similarity to equlibrium fibril length 
distributions.
313
 With a given shear stress the mean particle size can be calculated 
using equation (3.2).
315
 If a constant shear-stress is assumed, the median particle 
size increases proportionally to the stabilizing forces between the monomers. 
Alternating periods of seed growth and selective shearing would kinetically select 
seed population which are optimally fragmented. The amplification of seed 
populations that show a distinct mechanic fragmentability, however, would be 
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suppressed. Therefore, Selective Shearing Amplification (SSA) provides a concept 
for the in vitro selection of uniform seed populations from putative mixtures. 
 〈𝑛〉 = 𝑒𝑖𝑗  𝜏
−𝑞 (3.2) 
〈𝑛〉 is the asymptotic mean particle size 
𝜏 ist the shear stress (cp. Figure 3.8) 
𝑒𝑖𝑗 is a seed particle specific constant that ist proportional to the binding strength of the 
monomers, while 𝑞 has been found to be ~0.74 ± 0.02.315 
3.7.1 Acoustic SSA 
The concept of selective shearing had to be proven experimentally. On that purpose 
the in vitro amplification of hamster scrapie prions was surveyed in healthy brain 
tissue homogenates using an ultrasonic approach. It is known that PMCA reactions 
are cappable to amplify infinite amounts of infectious prions.
207
 Unfortunately, 
former approaches using a modified PMCA setup (cp. chapter 3.6.1, p. 47 et seqq.) 
revealed its inefficiency regarding a selective ultrasonic fragmentation (cp. 4.1, 
p. 65 et seqq.): We could demonstrate the feasibility of seeded conversion using the 
hamster prion strain Sc237. However, we also revealed technical drawbacks of the 
technique with respect to the total yield in PrP
Sc
 and the experiment reproducibility 
Although the experimental data indicated a promoting effect of bicelles we were not 
able to circumverent the observed variabilities in the reaction outcome. These 
problems could be attributed to the irregular oscillation behavior of the Cup Horn 
sonotrode, which represents a superficial source of sound. Contrary to PMCA, we 
used a sonotrode with a symmetric pattern for acoustic SSA. These patterns are also 
referred to as Chladni-figures (Ernst Florenz Friedrich Chladni, 1787). Chladni 
demonstrated that fixed metal plates can be excited to harmonic vibrations. The 
physical effect can be visualized if sand is sprinkeled on a vibration plane. The sand 
grains are repulsed from anti-nodes and are collected in nodes. The used sonotrodes 
mainly consists of relatively soft aluminum (AlMgSi, > 99% aluminium) and a 
Chladni-like pattern becomes visible by cavitational damage. Cavitation bubbles 
occur in areas of strongest amplitudes and implode on the sonotrode surface  
(Figure 3.2, p. 48). Resulting surface damage generates a Chladni-like pattern, the 
‘fingerprint’ of a standing wave, which represents a non-homogeneous sound power 
density distribution. In other words, the Chladni figure reflects the geometry of the 
harmonic surface oscillation function.  
For acoustic SSA we used a sonotrode replica which showed a clear five-fold 
symmetry in the Chladni-pattern (Chladni I, Figure 3.5). The Cup Horn was pro-
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duced by a local milling company. Shear forces are highly position dependent in the 
horizontal plane. Correct sample positioning, thus, is recommended for optimal 
PrP
res
 amplification yields.
316
 Consequently, a new ultrasonic setup was designed. 
And the sample positions were exactly matched to the anti-nodes of the Cup Horn 
(Figure 3.6). Ultrasound waves can be considered as alternating pressure amplitudes 
and solvent velocity amplitudes. Occurring velocity gradients, whether spatial or 
temporal, induce the fragmentation of contained particles by corresponding shear 
forces. As mentioned before, shear acts parallel to the cross-sections of a certain 
particle. Reaching a critical value it leads to the breakage at the weakest point. The 
shear stress, τ, is the product of the solvent viscosity, η, and the local velocity 
gradient, ∇𝑣 (3.3). The local velocity gradient is also known as shear rate, 𝐺. A 
multiplication of the particle velocity 𝒗(𝑡) with the acoustic pressure, 𝑝(𝑡), gives 
the sound intensity, 𝑰 (3.4).  
 𝜏 = 𝜂 × ∇𝑣 = 𝜂 × 𝐺 (3.3) 
 𝑰 =  𝒗(𝑡) ×  𝑝(𝑡) (3.4) 
Conclusively, the maximal pressure gradients are proportional to the magnitude of 
the maximal particle velocity gradients, ∇𝑣𝑚𝑎𝑥, if a constant mean sound intensity is 
assumed. Furthermore, the maximal shear stress is correlated with the pressure 
gradients (3.5). The effective acoustic pressure decreases inversely proportional to 
the distance of the sound source.
316
  
𝜏 ∝ ∇𝑝 (3.5) 
Thus, relative shear forces can be controlled by the sample height above the Cup 
Horn surface. Therefore, the sample mounting in acoustic SSA was planned to be 
height-adjustable (Figure 3.6). 
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Figure 3.5:  Cavitation damage patterns of customized harmonic sonotrodes 
   Replicas of the original Misonix M4,000 Cup Horn were analyzed with respect to 
their oscillation behavior. The images visualize the location of vibrational nodes. 
For that purpose new sonotrodes were covered with 1 cm of water and operated 
for 20 min at 37°C. Afterwards the surface was scanned as color image using a 
customary scanner. Every sonotrode showed a specific and unique pattern. The 
original Misonix Cup Horn (not shown) displayed a pattern similar to replica I-III. 
PMCA experiments which were performed using the height-adjustable sample 
holder, as described in Figure 3.3 C and Figure 3.4 (p. 49 and 50), were 
performed with replica I. A five-fold axial symmetry is evident for Chladni I and II, 
which were used in acoustic SSA (Figure 3.6). Contrast enhancement and further 
digital image processing accentuated the spatial distribution of the cavitation 
damage (Chladni I, bright colors, image provided by Dr. Thorsten Lührs, HZI), 
which coincides with the location of vibration nodes. In the interest of easier 
comparibility Chladni I and V are also shown as monochrome images which 
demonstrate the location of anti-nodes (black).  
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Figure 3.6: Acoustic Selective Shearing Amplification (SSA) 
   (A) Cross-sectional view of the designed setup for prion seed amplification by 
acoustic SSA. The ultrasonic generator (Misonix) can be lowered onto a secure 
stationary base. The sonotrode is fixed inside a water bath. Overflowing water 
(indicated in light blue) is collected and pumped out at the base of the device. The 
water is exchanged at a rate of six litres per minute. In our experiments water inlet 
and outlet were connected to a customary temperature-controlled water bath with 
an implemented pump. Height differences between pump and Cup Horn as well as 
tube lengths and dimensions were kept constant to guarantee a consistent water fill 
level. By this means the oscillation behavior of the sonotrode was kept 
reproducible. The water was renewed regularly. Bacteria growth was avoided, but 
more importantly detached metal particles were removed thereby. Ten independent 
drop rods end in aerosol tight screw cap tubes, which act as containers for the 
reaction vials. The sample positions were matched to the Chladni-figure of 
Chladni I (Figure 3.5).The positional reproducibility was better than ± 0.2 in the 
vertical direction and ± 0.5 mm in the plane direction. (B) Detailed view of a 
reaction vial in the water bath; The PCR tubes that are filled with the reaction mix 
are fixed inside of the sample containers (cp. Figure 3.7 B, p. 57). The Height can 
be adjusted using the drop rods at the top. The acoustic SSA was designed by 
Dr. Thorsten Lührs (HZI). The system is registered under the patent number 
EP2489427A1 and WO2012110570A1.
306,307
  
3.7.2 Test of the Acoustic SSA device 
To investigate the effect of different relative shear forces on the PrP
res
 amplification 
yield, acoustic SSA experiments with different sample heights were performed. 
Frozen scrapie brain homogenate was thawed and mixed with freshly prepared 
NBH (cp. 3.5, p. 44 et seqq.) by pipetting. If not mentioned otherwise a 2% (v/v) 
mixture of 10% (w/v) ScBH in 10% (w/v) NBH was used. The used normal brain 
homogenate, resp. the prepared reaction mix are cell suspensions. Even though 
complete protease inhibitor was added freshly and temperature was maintained at 
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4°C, aging, enzymatic degradation and of course precipitation processes cannot be 
excluded. Thus, long storage of the homogenates before usage was avoided. 
Aliquots of 125 µl (in thin-walled PCR-tubes) were flash frozen in liquid nitrogen 
for later use. Before using frozen aliquots were thawed at 22°C for 10 min under 
gentle agitation (Eppendorf Thermoshaker comfort, 750 rpm). The sample tubes 
were mildly spinned to avoid deposition of droplets in the lids. However, pellet 
forming was avoided. Tubes were mounted in the positioning ring as described in 
Figure 3.7 B. Then, the assembly was inserted into the ultrasonication waterbath. 
Care was taken to match the orientation of the Chladni figure (Figure 3.5). All drop 
rods were screwed down so that the samples slightly touched the surface of the 
sonotrode. Subsequently, the height was adjusted using a defined number of turns 
(1 turn of the height control screw is equivalent to 1 mm). All samples were adjust-
ed to the same height within a particular experiment. Otherwise acoustic SSA 
provides inconsistent data sets. This effect could be attributed to potential 
interferrences in the sound field expansion. If experiments with less than ten 
samples were peformed, water-filled PCR-tubes were mounted in the empty 
positions of the positioning ring. The reaction samples were processed at 240 W 
(corresponding to 85% set power at the Misonix 4,000) for three seconds every five 
minutes (264 cycles, 37°C) at heights of 0.5; 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 12; 14; 16 
and 18 mm (Chladni I, positions 1-10) and 0.5-12 mm (Chladni II, positions 1-8). 
Prior to each experiment the mounted reaction vials were exposed to one sonic burst 
(240 W for five seconds) to redissolve settled material. Trapped air bubbles and 
froth were strictly avoided. 
A list of all performed acoustic SSA experiments and the corresponding reaction 
parameters is given in Table A.3 (p. 92). 
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Figure 3.7: Positioning of reaction vials in PMCA and acoustic SSA 
   (A) PMCA: Positioning of tubes in Misonix 4,000 standard sample holder, the 
rotating sample holder as well as the height controlled sample holder (Figure 3.3, 
p. 49); The upper edge of the reaction mix ended with the lower edge of the sample 
holder, but no air filled gap was left. Thus, unwanted cavitation effects and 
therefore spurting into the lid of the PCR tube was avoided. (B) Acoustic SSA: An 
aerosol tight screw cap tube was attached to a drop rod for height adjustment. The 
screw cap tube was cut at the bottom, so that a PCR tube fit in tightly. The 
protuding lug of the PCR tube cap was removed with a scalpel. A silicone spacer at 
the end of the drop rod kept the PCR tube in position and perpendicular to the 
sonotrode surface. To avoid cavitation and spurting of the reaction mix, the air 
filled part of the PCR tube was kept within the watertight screw cap tube. 
3.7.3 Mechanical Selective Shearing Amplification (SSA) 
To validate the principle of selective shearing for the selection of seed population an 
alternative shearing meachanism was tested. Mechanical shear stress can be 
generated in the laminar flow of an incompressible viscous solvent if it is filled in 
the gap between two coaxial cylinders which are rotating relative to one another 
(Couette flow).
317
 The movement provides a solvent velocity gradient between the 
outer and the inner cylinder and creates homogenous shear fields that are 
proportional to the rotation frequency. Apart from the rotor shape, the viscosity and 
the space between rotor and stator are directly correlated to the applied shear 
force.
318
 Using custom-designed, induction-driven dispersion tools (Heidolph, 
Silent Crusher S, tool 3F; rotor radius kR = 1 mm, 0.3 mm gap width) as shear-
generators, homogeneous and reproducible shear forces could be applied to 
arbitrary reaction volumes (Figure 3.8 B). 
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3.7.4 Mechanical SSA array 
Mechanical SSA provides the opportunity to test different parameters (e.g. different 
shearing conditions, cycle times, interprocessing delay, buffer compositions, 
additives) using several geometrical identical shear-generators (disperion tools 3F, 
Silent Crusher S from Heidolph, Schwabach, Germnay) in parallel. To make this 
possible the SSA-array was built (Figure 3.8 A, C and D). It consists of 21 slots for 
shear-generators in a temperature controlled environment. Using computer 
controlled switching relays, every single device can be programmed separately for 
experiments using rotation frequencies ranging from 40 to 1,201 Hz. 
 
Figure 3.8:  Mechanical Selective Shearing Amplification (SSA) array 
   (A) The SSA array is a self-built, temperature-controlled device. It can indepen-
dently operate 21 identical shear generators (disperion tools 3F, Silent Crusher S 
from Heidolph, Schwabach, Germnay). The shear generators can be individually 
controlled and are located in expandable sockets. Processing time, interprocessing 
delay as well as total reaction time can be altered. A water pump connected to a 
copper coil ensures the temperature exchange. Several fans provide a homogenous 
temperature distribution. (B) Schematic illustration of a shear generator; The 
principle of a Couette-type shear generator is explained. The shear rate depends 
on the radius of the rotor r, its frequency v and the gap of height, h, between rotor 
and stator. The shear force is determined as a product of the shear rate and the 
viscosity, η, of the solvent. The shear force is proportional to the rotation frequency 
of the rotor.
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 (C) Detailed view of the SSA array; A row of seven shear 
generators is shown. Each device is preasembled in a laminar-flow hood and 
sealed aerosol tight. (D) Detailed view of the SSA array; In the foreground a 
driving unit, the corresponding mainboard with connecting cables and the reaction 
tube can be seen. The mechanical SSA was designed by Dr. Thorsten Lührs (HZI). 
The system is registered under the patent number EP2489427A1 and 
WO2012110570A1.
306,307
 
On that purpose the original setup of the shear-generators was modified. Removing 
the base only the drive unit ring and the mainboard were kept. The implemented 
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potentiometer was replaced by a more accurate component. Connecting the power 
supply line to customary relay cards, computer programmable on-/off-cycles were 
made possible. A second, independent power supply line was interrupted by a 
multi-pole plug. Read directly from the mainboard circuit, the frequency signal was 
looped through this plug. This construction made it possible to start individual 
shear-generators independently from the implemented relay card circuit and, 
moreover, a fine-adjustment of the frequency. The frequency range of the driving 
unit could be extended by fine adjustment of the onboard potentiometers. The 
power supply was ensured by commercially available power packs.  
To guarantee reproducible reaction sequences, consistent movement of the 
dispersion tool rotors is inevitable. Teflon™ bearings from Heidolph served the 
purpose, but they showed deficiencies especially in longer runs and primarily with 
processing frequencies above 600 Hz. Abrasion and formation of particles often 
influenced the rotor movement. Related to these problems, imbalances and local 
heat buildups cropped up. A further problem was the reusability of the commercial 
bearings. Once removed from the stator the Teflon™ parts could not be reused, but 
disassembling of the shear-generators was strongly recommended for successful 
decontamination (cp. 3.3, p. 41 et seqq.). To solve the problem the bearings were 
replaced by customary Teflon™ tubes (Bola, Grünsfeld, Germany). Cut to the 
required size and a little shortened compared to the original parts, self-made 
bearings could be henceforth used as disposable parts. To ensure smooth rotor 
movement the edges were scrupulously burred using a scalpel. Due to production 
the wall size of Teflon™ tubes can vary. Therefore self-made bearings were often 
squeezed to a rectangular shape. Thus, the rotor was girded more tightly and 
wobbling was reduced. Prior to each experiment all shear-generators were tested 
(cp. 3.7.11, p. 62 et seqq.). The procedure avoided rotor dropouts, but also polished 
new bearings and removed barely visible imperfections. To guarantee a better 
intermixture of the reaction mix holes were drilled in the stators of all shear-
generators.  
3.7.5 Proof of principle  
To test the feasibiltiy of shear promoted selective prion amplification a  single non-
modified shearing device was tested to amplify hamster prions of different prion 
isolates (Sc237 and 263K). A 10% (w/v) ScBH was diluted 1:10 into a 10% (w/v) 
NBH and processed for 60 seconds every nine minutes (144 cycles). Processing was 
performed at 0; 15,000; 30,000; 45,000 and 75,000 rpm. The whole shearing device 
was incubated in an incubator at 37°C. Alternating processing and incubation steps 
were realized by a customary switching relay. 
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3.7.6 Test of the SSA array 
The comparison of the hamster prion strains Sc237 and 263K was repeated using 
the SSA array. Beside parallel processing the new hardware allowed a higher 
maximal processing frequency as well as a finer adjustment of the processing 
frequencies. Thus, a logarithmic scale increment of 35% per interval was selected. 
A 10 % (w/v) ScBH was diluted 1:10 into a 10% (w/v) NBH and processed for 
60 seconds every 60 minutes (24 cycles, 37°C). Processing was performed at 40; 
54; 72; 96; 129; 173; 232; 311; 417; 559; 749 and 1,004 Hz. For non-seeded control 
reactions a 10% (w/v) NBH was processed for 60 seconds every 60 minutes 
(24 cycles, 37°C, 900 µl per reaction). Processing was performed at 54; 173 and 
417 Hz. 
3.7.7 The kinetic buildup of PrPres 
To analyze the kinetic buildup of PrP
res
 in subsequent mechanical SSA experiments 
samples of ~20 µl were taken at different time points. On that purpose the reactions 
vials were modified. The thread of a customary HPLC vial  with screw cap and 
septum  was cut and welded on the reaction vial using a gas jet. Tuberculin syringes 
could be used for sampling. Considering the volume decrease with each taken 
sample a higher reaction volume (1,150 µl instead of 900 µl) was chosen. To avoid 
over-processing of the homogenate not more than eight samples (~160-200 µl) were 
taken from running reactions. Furthermore, the edges of the rotor blade wer rounded 
down by manual grinding to minimize vibrations of the shear-generators. 
To investigate the influence of the cycle time on the amplification of Sc237 prions 
the kinetic buildup was surveyed. A 10 % (w/v) ScBH was diluted 1:50 into a 
10% (w/v) NBH and processed for five seconds every 5/15/30/60 or 90 minutes 
(480/160/80/40 or 27 cycles, 37°C). Processing was performed at 1,000 Hz.  
Subsequently a comparison of the kinetic buildup of PrP
res
 was performed for the 
prion strains Sc237 and 263K. A logarithmic scale increment of 35% per interval 
was selected. Based on the results of the prior experiment a 10 % (w/v) ScBH was 
diluted 1:50 into a 10% (w/v) NBH and processed for 5 seconds every five minutes 
(264 cycles, 37°C). Processing was performed at 96; 119; 150; 189; 238; 300; 476; 
600; 756; 953 and 1,201 Hz. 
Interprocessing delay 
Without affecting the processing the influence of a contious cycle time increase on 
the amplfication of Sc237 prions was investigated. A logarithmic scale increment of 
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35% per interval was selected. A 10 % (w/v) ScBH was diluted 1:50 into a 
10% (w/v) NBH and used as a reaction mixture. The increase of the cycle time is 
defined by equation (3.6). Processing was performed at 96; 119; 150; 189; 238; 
300; 476; 600; 756; 953 and 1,201 Hz. 
 
𝐶(𝑡) = 𝐶1 + (𝐶2 − 𝐶1) (1 − exp (−
1
𝐶𝑘 ∗ 𝑡
)) 
𝐶1 < 𝐶2 
(3.6) 
𝐶1 represents the start cycle time (5 min, t=0).  
𝐶2 is the final cycle time (10 min). 
𝐶𝑘 determines the initial slope (=18).  
3.7.8 Non-processed reactions 
Non-processed control reactions were performed to investigate the influence of 
processing in mechanical SSA using the prion strains Sc237 and 263K as seeds. A 
10 % (w/v) ScBH was diluted 1:50 into a 10% (w/v) NBH and incubated in the SSA 
array at 37°C for 24 h. 
3.7.9 Effect of seed and homogenate treatment 
Different Sc237 seed dilutions were tested in mechanical SSA. Therefore, a 
10 % (w/v) ScBH was diluted 1:25, 1:50, 1:75, 1:100, 1:125, 1:150, 1:75, 1:200 and 
1:225 into a 10% (w/v) NBH and processed five seconds every five minutes 
(288 cycles, 37°C). Processing was performed at 600 Hz.    
Furthermore, the influence of a reaction mixture (NBH + Sc237BH) pretreatment 
was tested. Therefore, a 10 % (w/v) ScBH was diluted 1:50 into a 10% (w/v) NBH 
and span at 2,000; 5,000; 10,000; 15,000 and 25,000 x g for 10 min at 4°C. The 
supernatant was processed five seconds every five minutes (576 cycles, 37°C). 
Processing was performed at 1,000 Hz.    
Additionally, the effect of a NBH pretreatment was surveyed. A suspension of 
freshly prepared 10% (w/v) healthy hamster brain in conversion buffer was span at 
25,000 x g for 10 min at 4°C. The supernatant was used to create 1:50 dilution of 
10% (w/v) Sc237BH, which was processed five seconds every five minutes 
(576 cycles, 37°C). Processing was performed at 96; 119; 150; 189; 238; 300; 476; 
600; 756; 953 and 1,201 Hz. 
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3.7.10 Effect of SDS 
To investigate the effect of denaturing agents in selective shearing amplification 
reactions SDS was added to the reaction mixture. Therefore, 10 % (w/v) NBH was 
prepared using conversion buffer which already contained SDS (to reach final 
concentrations of 1; 2 or 5 mM SDS in the reaction mixture). A 10 % (w/v) ScBH 
was diluted 1:50 into the NBH and processed five seconds every five minutes 
(576 cycles, 37°C). Processing was performed at 150 and 1,201 Hz. 
3.7.11 Reaction mix and preparation steps for mechanical SSA 
Frozen scrapie brain homogenate was thawed and mixed with freshly prepared 
NBH (cp. 3.5, p. 44 et seqq.) by pipetting. If not mentioned otherwise a 2% (v/v) 
mixture of 10% (w/v) ScBH in 10% (w/v) NBH was used. The used normal brain 
homogenate, resp. the prepared reaction mix are cell suspensions. Even though 
complete protease inhibitor was added freshly and temperature was maintained at 
4°C, aging, enzymatic degradation and of course precipitation processes cannot be 
excluded. Thus, long storage of the homogenates before usage was avoided. In the 
normal case, buffer completion, preparation of homogenate and reaction mixture, 
sample aliquotation as well as the final shear-generator assembly were done in one 
go. In order to minimize the time between homogenate preparation and the reaction 
start, experiments were always prepared by two persons. 
On that account experiment preparations followed the following steps: 
1. Pre-heating of the mechanical SSA array; if necessary water refill 
The SSA array needs at least 2 hours to heat up from room temperature to 
37°C. Especially for reactions, which are planned to run longer than 
24 hours, the water level should be checked from time to time. 
2. Shear-generator decontamination, washing, drying, assembly 
Shear-generators were decontaminated like described in chapter 3.3 (p. 41 et 
seqq.). After drying the stators were carefully equipped with new self-made 
Teflon™ bearings. The length of the bearings was taken over from the 
original part size (Heidolph, Schwabach, Germany), but they protuded the 
stator by not more than 0.5 mm. These Teflon™ parts were simply cut from 
a tubing (Bola, Grünsfeld, Germany) with aid of a brass tube template, which 
fitted the inner diameter. Edges were cut with a straight scalpel grind, leaving 
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as few as possible slanted burrs. Thereafter, the edges were smoothed with 
one circular movement of the hand using a curved scalpel grind.  
3. Test run of the shear-generators, followed by a centrifugal drying  
 
For a successful run of the shear-generators, especially at frequencies higher 
than 600 Hz, the bearings should fit tightly. To avoid squeezing of the 
bearing only the first millimeters were pressed into the stator using the bare 
hands. Using the rotor the rest of the tubing was stuffed into the stator. 
Normally a little frictional resistance should be perceptible while carefully 
pressing the rotor down. Drawing out the rotor, the bearing should remain 
within the stator. Less friction often leaded to wobbling effects and therefore 
an inaccurate processing frequency of the particular shear-generator. 
Inappropriate edges often caused particles during the test run, leading to 
clanking noise of the tools. Disassembling the shear-generators and rinsing 
with deionized water fixed the problem in most of the times. Anyway, an 
exchange of the bearing was often mandatory. 
All assembled shear-generators were tested at 1,000 Hz with 900 µl 
deionized water in a 1.5 ml reaction tube. On that account tools were run for 
~30 seconds to check for vibrations. Trapped air bubbles could cause 
unwanted wobbling and noise in the first seconds, but long-lasting problems 
during the run were always an indication for grit and/or the necessity for a 
bearing exchange. In contrast to lower frequencies, shear-generators, which 
were supposed to run with more than 1,000 Hz, were tested at 1,201 Hz.  
After testing each array position was set to the wanted frequency using the 
particular tool. 
Afterwards the water was removed from the attached 1.5 ml-reaction tubes. 
Reassembled with the empty tubes the shear-generators were transferred into 
50 ml-reaction tubes and centrifuged two times for two minutes at 500 x g 
(higher speeds can cause non-reparable damage of rotor and stator).  
4. Preparation of ice bath; pre-cooling of buffer, reaction tubes and dounce 
homogenizer   
 
5. Preparation of NBH and reaction mixture (cp. 3.5, p. 44 et seqq.) 
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6. Assembly of shear-generators and incubation 
As not indicated otherwise 900 µl aliquots were filled into decontaminated 
reaction tubes (1,150 µl if kinetic experiments were performed). The lid of 
the tubes was removed beforehand. One by one, each 3F dispersion tool was 
assembled and incubated for 20 min at 37°C. To avoid leakage of 
contaminated liquids/aerosols and/or loosening of the reaction vial or the 
remove retainer one layer of parafilm was wrenched around the dispersion 
tool. During incubation the parameters for the run (duration, cycle time 
(on/off-time), interprocessing delay) were set.  
7. Reaction start  
A list of all performed mechanic SSA experiments and their reaction parameters is 
given in Table A.4 (p. 94). 
 
4 Results 
4.1 PrP
Sc
 amplification by ultrasonic processing 
4.1.1 Protein Misfolding Cyclic Amplification (PMCA) 
Using the hamster prion seed Sc237 the experiments provided expected results: 
Protease digests and subsequent SDS-PAGE and western blot analysis showed 
product sizes of 37 kDa and high protease resistance of converted PrP
C
 in all PMCA 
experiments. The reaction products of the initial round were sucessfully used to 
seed fresh NBH in a subsequent conversion reaction (serial PMCA). Decreased seed 
concentrations provided less amplification yield, as shown in Figure 4.1 A. 
However, the the the total yield of PrP
res
 showed significant variability if samples 
were variously positioned on the standard sample holder (Figure 4.1 B). 
Centerpiece of the Misonix device is the circular surface of a 20 kHz sonotrode, 
which is clamped in a sealing plastic ring – the base of the overlying water bath. 
Experiments with the centered sample holder indicated a higher conversion 
efficiency near to the center of the sonotrode, but the reaction outcome still turned 
out to be strongly variable with respect to the yield of PrP
res
 (Figure 4.1 D).  
Bicelles clearly showed positive effects in PMCA reactions. To avoid different 
processing tubes with different biochemical compositions were placed in direct 
neighborhood. Interestingly, bicelles without charge (no phosphoserine was added) 
provided the highest yield of PrP
res
. Compared to standard reactions also DHPC 
alone, at concentrations of 25 and 50 mM, caused a higher reaction outcome in one 
of the experiments (Figure 4.1 C). The positive effect of bicelles became even more 
manifest if amplification was tested on the centered sample holder (Figure 4.1 D).  
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Figure 4.1: PMCA experiments 
   (A) Seed dependence of Sc237-seeded PMCA; Different dilutions of ScBH in NBH 
were tried for conversion reactions. Particular samples (10% v/v) were used to 
seed a further reaction round (serial PMCA). (B) Position effects in PMCA; 
Comparison of simultaneously performed PMCA reactions on different postions (1-
12) of the original sample holder (Misonix). (C) Effect of bicellar mixtures in 
PMCA; Different negatively charged bicellar mixtures were added to PMCA 
reactions (25 mM final concentration). Beside this the influence of DHPC was 
tested. (D) Radius dependence in PMCA; The oscillation behavior of the sonotrode 
(replica I) was analyzed using a centered rotating sample holder. Plots of two 
separate experiments are shown. Samples with and without bicelles (25 mM, w/o 
PS) were alternately mounted on the sample holder. Experiment results are 
therefore illustrated as two graphs. For all experiments(except (A)) 5% (v/v) ScBH 
(Sc237) in NBH was used as reaction mix. Reactions were performed in 100 or 
200 µl aliquots with a power level of 90%, 40 s processing, 59.67 min incubation 
and 24 or 48 h duration. The original Misoinix 4,000 setup was used (sonotrode 
replica I, standard sample holder resp. a rotating sample holder). Samples were 
digested witch 50 µg/ml proteinase K (PK) at 37°C for 1 h and analyzed by 
western blotting (using the PrP-specific 6H4 antibody) and 1D densitometry. 
By comparing the cavitation damage profiles on the surface of the recreated Cup 
Horns individual patterns of irregular shape could be observed (Figure 3.5, p. 54) 
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which resemble the geometry of the underlying harmonic surface oscillation 
function. The irregular shape of the cavitation damage pattern gave rise to the 
assumption that the soundwaves are not emitted evenly across the surface of the 
Cup Horn. With the purpose to understand the influence of the oscillation behavior 
on the amplification of PrP
res
 we considered to use fixed sample positions. Thus, a 
new sample holder was developed. The position of the reaction vials were matched 
to the estimated anti-nodes of replica I (Figure 3.3 C and Figure 3.4). Nevertheless, 
the determination of the PrP
res
 amplification yields of the hamster prion isolates 
263K and Sc237 at multiple heights still revealed high variability and limitied 
position comparability (Figure 4.2). 
 
Figure 4.2: Height profiles of Sc237 and 263K hamster prion seeded PMCA reactions 
   Height-dependent amplification of PrP
res
 was analyzed using a height-adjustable 
sample holder with fixed positioning (sonotrode replica I). 5% (v/v) ScBH (Sc237) 
in NBH was used as reaction mix. Reactions were performed on separate days in 
100 µl aliquots with a power level of 90%, 60 s processing, 9 min incubation and 
24 h duration. Afterwards, samples were digested with 50 µg/ml proteinase K (PK) 
at 37°C for 1 h and analyzed by western blotting (using the PrP-specific 6H4 
antibody) and 1D densitometry. The dashed line indicates the amount of seed used 
for these reactions. 
Conclusions 
PMCA was successfully established using the hamster prion strain Sc237. Never-
theless, despite the fact that non-charged bicelles positively influenced the 
amplification of PrP
res
, the reaction yield still was subject to strong fluctuations 
which can be attributed to the acoustic behavior of the Cup Horn sonotrode. Each 
sonotrode replica yields a specific and unique pattern which can readily explain the 
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position effects in standard PMCA reactions. Thus, the acoustic SSA concept was 
developed which uses a sonotrode with a defined oscillation behavior. 
4.2 Acoustic SSA 
Contour plots of acoustic SSA experiments using the hamster prion strains Sc237 
and 263K as seeds are shown in Figure 4.3 (Chladni I). The normalized PrP
res
 
amplification yield is plotted against the sonotrode position and height above the 
surface. Both strains amplified well at multiple positions near the Chladni-horn 
surface. Carried out with the hamster 263K strain, the yield decreased with 
increasing heights. In contrast, significant amplification of PrP
res
 was also observed 
at heights of 3 mm and 8 mm using the Sc237 strain. In a second experiment we 
tested a new sonotrode (Chladni II), which showed a less symmetric Chladni 
pattern. Although it is still evident that both prion strains are distinctive reagarding 
their amplification behavior, the height optima clearly differ from the experiments 
with Chladni I. While siginificant amplification was observed at 0.5 mm and 2 mm 
in samples seeded with 263K, the height optimum for Sc237 was observed between 
4 mm and 6 mm. 
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Figure 4.3:  Height profiles of Sc237- and 263K-seeded conversion reactions in ultrasonic 
SSA 
    Intensity contour plots are displayed. Reactions were arranged in heights of 0.5, 1, 
1.5, 2, 3, 4, 5, 6, 8, 10 and 12 mm above the sontrode surface of Chladni II. 
Additional heights of 14, 16 and 18 mm were tested for Chladni I. Cycles were set 
to 5 min with 5 s processing at 85%. 5% (v/v) ScBH (Sc237) in NBH was used as 
reaction mix. Reactions were performed in 120 µl aliquots with a duration of 22 h. 
Samples were digested with 50 µg/ml proteinase K (PK) at 37°C for 1 h and 
analyzed by western blotting (using the PrP-specific 6H4 antibody) and 1D 
densitometry. 
Conclusions 
As mentioned before we anticipated that different structured proteopathic seeds 
might be selectable based on their specific fragmentability (cp. 3.7, p. 51 et seqq.). 
Indeed, the distance to the sound source influences the acoustic pressure, which in 
turn is correlated with the relative shear force (cp. 3.7.1, p. 52 et seqq., equations 
(3.3)-(3.5)). The experimental data clearly showed that the PrP
res
 amplification yield 
is dependent from the sample height above the sonotrode surface, but also revealed 
that there is a clear distinction between both prion strains. The results also outlined 
that the vibrational pattern can dramatically influence the reaction outcome (Figure 
4.3, p. 69). To validate the observed strain differences the concept of SSA was also 
tested using mechanical generated shear stress.  
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4.3 Mechanical SSA 
4.3.1 Proof of principle 
The feasibiltiy of shear promoted selective prion amplification was initially tested 
using a single shearing device. The amplification of the hamster prion strains Sc237 
and 263K was surveyed at 0, 15, 30, 45, 60 and 75 krpm. Processing was performed 
for 60 s every nine minutes  using a single and non-modified shear-generator. PrP
res
 
molecules which were amplified by mechanical SSA showed similar electrophoretic 
behavior and resistance to protease digest compared to conversion products 
generated via PMCA. Furthermore, the results revealed differences between 263K- 
and Sc237-seeded amplification reactions with resprect to the processing frequency. 
Seeded with brain tissue homogenate from Sc237 hamsters the highest PrP
res
 
amplification yield was achieved using a speed of rotation of 30,000 rpm. In 
contrast, 263K seeds caused a single amplification optimum at 45,000 rpm. 
Moreover, the ampfliciation yield tended to zero at 60,000 rpm and 75,000 rpm. 
(Figure 4.4) Nevertheless, the amplfication factors did not exceed a value of five. 
 
Figure 4.4:  Initial proof of principle with mechanical SSA reactions 
   Amplification of PrP
res
 was tried out using a single customary dispersion tool. 
These mechanical SSA reactions were either seeded with Sc237 or 263K  hamster 
prions. The amount of amplfied PrP
res
 is shown as a function of rotational speed. A 
mixture of 5% (v/v) scrapie brain homogenate in normal brain homogenate was 
used for conversion reactions. Processing speeds of 0, 15,000, 30,000, 45,000, 
60,000 and 75,000 rpm were roughly set with the integrated potentiometer of the 
magnetic drive. The reaction was performed in an incubator at 37°C for 22 hours 
with a cycle setting of one minute processing and nine minutes incubation. 
Automatic switching between processing and incubation steps was achieved with a 
customary switching relay. Samples were digested witch 50 µg/ml proteinase K 
(PK) at 37°C for 1 h and analyzed by western blotting using the PrP-specific 6H4 
antibody and 1D densitometry. 
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Conclusions 
Apart from the ultrasonic approach (cp. 4.1, p. 65 et seqq.) the applicability of shear 
promoted selective prion seed amplification was successfully tested using 
mechanical shear. As observed in acoustic SSA the prion strains 263K and Sc237 
showed clear differences with respect to the applied shear forces. In order to 
achieve a better comparability, further experiments were performed by parallel 
processing at different shear forces. For that purpose an array of shear generators 
was used. Beside parallel processing the new hardware allowed a higher maximal 
shear rate as well as a finer adjustment of the processing frequencies (cp. 3.7.4, p. 
58 et seqq.). It was assumed that longer incubation intervals (growth phases) might 
positively influence the amplification factor in the following experiments.  
4.3.2 Test of the SSA array 
As a starting point, parallel processing of Sc237- and 263K-seeded reactions was 
peformed with the SSA array. A logarithmic scale increment of 35% per interval 
was selected for frequencies ranging from 40 to 1,004 Hz (2,400-60,240 rpm). To 
avoid potential overprocessing and sample heating the reactions were processed 
using 22 cycles of 60 seconds processing and 59 minutes incubation. To 
demonstrate that the generation of protease resistant PrP
res
 is not due to non-specific 
PrP aggregates, non-seeded control experiments were also performed. Two distinct 
optima of amplification could be identified at processing frequencies of 72 Hz and 
417 Hz for the hamster prion strain Sc237 (Figure 4.5 A). In contrast, only one 
optimum near the maximal processing frequency was obseved when the mechanical 
shearing amplification experiment was repeated using the 263K strain (Figure 
4.5 B). PrP
res
 could only be detected in prion-seeded reactions (Figure 4.5 C).  
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Figure 4.5: Influence of frequency, seed and incubation on mechanical SSA reactions  
   Amplification of PrP
res
 was tried out using an array of 12 shear-generators 
simultaneously using a frequency range from 40-1,004 Hz. These mechanical SSA 
reactions were either seeded with Sc237(A) or 263K (B) hamster prions. The 
amount of amplfied PrP
res
 is shown as a function of rotational speed. (C) Non-
seeded SSA reactions: Observed speed optima for the hamster prion strain Sc237 
were tested without addition of infectious brain homogenate. The reactions were 
performed in the SSA array at 37°C for 22 h with a cycle setting of one minute 
processing and 59 minutes incubation. Except for non-seeded reactions a mixture 
of 5% (v/v) scrapie brain homogenate in normal brain homogenate was used. 
Samples were digested witch 50 µg/ml proteinase K (PK) at 37°C for 1 h and 
analyzed by western blotting using the PrP-specific 6H4 antibody, followed by 1D 
densitometry. 
Conclusions 
The finer resolution of the processing frequencies and the changed cycle times 
revealed two amplification optima for the Sc237 strain, while only one clear 
optimum was found for 263K. In order to survey these differences which already 
caught our attention in acoustic SSA (cp. 4.2, p. 68), it was decided to observe the 
time-dependent course of the mechanical SSA reactions. In contrast the non-seeded 
control experiments clearly showed that the generated PK resistance resulted not 
only from a spontaneous aggregation of the cellular prion protein due to the applied 
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shear stress. Compared to the initial tests with a single shear generator (cp. 4.3.1, 
p. 70), longer incubation periods seemed to increase the amplification yield, which 
leaded to the decision to systematically test different time settings. Furthermore, we 
observed unwanted sample heating due to the processing. Thus, the following SSA 
experiments were performed using shorter processing intervals and modified rotor 
blades. 
4.3.3 The kinetic buildup of PrPres 
To analyze the kinetic buildup of PrP
res
 in subsequent mechanical SSA experiments 
samples of ~20 µl were taken at different time points. For these experiments the 
edges of the rotor blade wer rounded down by manual grinding to minimize 
vibrations of the shear-generators (cp. 3.7.7, p. 60 et seqq.). To investigate the 
influence of the cycle time on the amplification of Sc237 prions the kinetic buildup 
was surveyed at a rotor frequency of 1,000 Hz for cycle times of 5, 15, 30, 45, 60 
and 90 minutes. In order to avoid heating of the reactions a processing time of five 
seconds was chosen. The highest amplification rate was obtained with the shortest 
cycle time of five minutes. Within six to twelve hours the PrP
res
 buildup reached 
half-maximal values. (Figure 4.6)  
 
Figure 4.6: Mechanical Shearing Amplification (SSA) array – Influence of the cycle time 
   Influence of the cycle time on the Sc237 prion seed amplification behavior. Tools 
were run at a rotation frequency of 1,000 Hz. A mixture of 2% (v/v) scrapie BH in 
NBH was used for conversion reactions (reaction volume: 1,150 µl). The reactions 
were performed in the SSA array at 37°C for 40 hours with a cycle setting of five 
seconds processing. Modified reaction tubes were used to extract ~30 µl samples 
at different time points. Samples were digested with 50 µg/ml PK at 37°C for 1 h 
and analyzed by western blotting using the PrP-specific 6H4 antibody, followed by 
1D densitometry. 
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Maintaining a setting of five seconds processing and a cycle time of five minutes 
the entire accessible rotation frequency range (40-1,201 Hz) was scanned. A 
logarithmic scale increment of 26% per interval was selected.  The experiment was 
also repeated using the hamster prion strain 263K to compare the kinetic PrP
res
 
amplification traces of both prion isolates. The kinetic data revealed significant 
differences between both prion strains. The initial PrP
res
 buildup rate for Sc237 
turned out to be six times faster compared to the slow initial rate of 263K, which 
showed a sigmoidal shape (Figure 4.7 A and D). Furhtermore, both strains again 
showed distinct optima of amplfication with respect to the processing frequency. 
Regarding the Sc237 strain three optima were identified at processing frequencies 
of 150, 600 and 1,201 Hz. In accordance with earlier results (cp. Figure 4.5, p. 72) 
only one optimum near the maximal processing frequency was observed when the 
conversion reaction was seeded with the 263K strain (Figure 4.7 B/C, E/F). 
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Figure 4.7:  Mechanical Selective Shearing Amplification of hamster prion seeds 
Amplification of PrP
res
 in mechanical SSA reactions seeded with Sc237 (A-C) or 
263K (D-F) hamster prions. Data is shown as a function of rotation frequency and 
of time (B and E). A corresponding kinetic trace of PrP
res
 amplification at the 
observed shearing optima of 150 Hz, 600 Hz and 1,200 Hz is also shown (A and 
D). A mixture of 2% (v/v) scrapie BH (Sc237 resp. 263K) in NBH was used for 
conversion reactions (reaction volume: 1,150 µl). The reactions were performed in 
the SSA array at 37°C for 24 hours with a cycle setting of five seconds processing 
and four minutes and 55 seconds incubation. Modified reaction tubes were used to 
extract ~30 µl samples at different time points. Samples were digested with 
50 µg/ml PK at 37°C for 1 h and analyzed by western blotting using the PrP-
specific 6H4 antibody, followed by 1D densitometry. Corresponding western blots 
of the PK resistant PrP
res
 bands are shown for each time point (C and F). The 
amplification factors relative to the initial seed obtained at each time point are 
plotted against the processing frequencies. 
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Interprocessing delay 
An increased cycle number did not necessary lead to a further increase of the 
reaction yield and often caused an abatement of already converted PrP. Above all 
this phenomenon became apparent in reaction samples which were processed with 
frequencies higher than 600 Hz. An explanation might be an over-processing of the 
samples. The western blot in Figure 4.9 C (> 24 h) exemplifies this effect quite 
explicitly. To counteract the early occurring stationary phase of the PrP
res
 buildup 
and to avoid potential over-processing, the former approach was reconsidered. 
Without affecting the processing the influence of a contious cycle time increase was 
investigated (Figure 4.8). Compared to an SSA experiment with a constant cycle 
time the amplification yield at processing frequencies of ≥ 600 Hz could be 
significantly increased (Figure 4.8 A and B). Two optima of amplification could be 
identified at processing frequencies of 600 Hz and 1,201 Hz. On the other hand, 
amplification at 150 Hz was comparatively low, showing similar PrP
res
 replication 
as in the standard experiment (cp. Figure 4.7 B). Figure 4.8 (A and C) exhibits the 
quantitative analysis of such an experiment.  
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Figure 4.8: Extended cycle time in mechanical SSA 
   The amplification of PrP
res
 in mechanical SSA reactions is shown. The cycle time 
was continously increased. (A) Data is shown as a function of rotation frequency 
and of time. (B) Corresponding kinetic trace of PrP
res
 amplification at the observed 
shearing optima of 1,200 Hz, with and without modified cycle setting. (C) Corres-
ponding western blots of the PK resistant PrP
res
 bands are shown for each time 
point. The amplification factors relative to the initial seed obtained at each time 
point are plotted against the processing frequencies. (D) The cycle time is plotted 
as a function of time. A mixture of 2% (v/v) scrapie BH (Sc237) in NBH was used 
for conversion reactions (reaction volume: 1,150 µl). The reactions were 
performed in the SSA array at 37°C for 48 hours. Modified reaction tubes were 
used to extract ~30 µl samples at different time points. Samples were digested with 
50 µg/ml PK at 37°C for 1 h and analyzed by western blotting using the PrP-
specific 6H4 antibody, followed by 1D densitometry. 
Conclusion 
The kinetic buildup of PrP
res
 could be closely monitored for a timeframe of 
24 hours. Compared to the previous experiments (cp. 4.3.2, p. 71 et seqq.) the ad-
justment of the processing and incubation time dramatically increased the PrP
res
 
amplification yield for Sc237-seeded SSA reactions. Of course, the influences of the 
hardware adjustments and the different processing frequencies also have to be 
considered. Nevertheless, the maximum amplification factors of 263K are less high. 
The influence of the cycle time setting became particularly obvious if the SSA 
reactions were performed with an interprocessing delay. Interestingly, these settings 
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only positively influenced the growth rates above 600 Hz. Based on that 
observation, the observed amplification optima and divergent buildup rates, Sc237 
and 263K might consist of conformationally different PrP
res
 populations.  
4.3.4 Non-processed reactions 
Despite the fact that alternating steps of processing and incubation support PrP 
conversion in vitro, it has been shown that limited amplification of PK resistant PrP 
is also feasible in prion seeded tissue homogenates without external ascendancies 
except for temperature.
198
 To emphasize the influence of processing in mechanical 
SSA, the kinetic buildup of PrP
res
 was also investigated in non-processed control 
reactions. The amplification factor of control reactions seeded with the prion strain 
263K did not exceed a value of five after 24 hours, while Sc237-seeded reactions 
did not exceed a value of 15 (Figure 4.9 B). 
Conclusion 
Alternating cycles of mechanical shearing and incubation dramatically increase the 
PrP
res
 amplification. 
4.3.5 Effect of seed and homogenate treatment 
As mentioned previously the addition of scrapie brain homogenate is crucial for 
successful conversion in brain homogenate based SSA reactions (cp. Figure 4.5 B). 
Therefore and to test the potential of the SSA assay, different seed dilutions were 
tested. All tools were run at the maximum possible processing frequency of 
1,201 Hz to ensure the highest possible amplification factors. The plot in Figure 
4.9 C shows the normalized time course of the PrP
res
 buildup with repsect to 
different prion seed dilutions. The corresponding western blot is shown in Figure 
4.9 D. The experimental results revealed that dilution factors of 1:150 or higher 
were not sufficient to generate verifiable amounts of PK resistant PrP within 48 
hours. Similar effects on the kinetic buildup of PrP
res
 could be observed if the 
reaction mixture (ScBH (Seed) + NBH (Substrate)) was spun down prior to a 
selective shearing amplification experiment. It was envisaged that a centrifugation 
of the seeded brain homogenate could lead to a removal of potential conversion 
inhibiting compounds. Although almost the same band intensity is reached after a 
total reaction duration of over 24 h, a flattened shape of the PrP
res
 buildup rate was 
observed if the reaction mixture was centrifuged at 2,000 x g. Especially a 
centrifugal acceleration of ≥ 10,000 x g resulted in almost no amplification (Figure 
4.9 A).  
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Since good conversion results in PMCA were achieved with native PrP, which was 
purified from NBH
209
, a pretreatment of the NBH was considered. The necessary 
amounts of purified native PrP for SSA reactions exceeded the limitation of the 
complex purification protocol. Thus, freshly prepared NBH was suspendend by 
centrifugation (25,000 x g, 10 min, 4°C). The supernatant was mixed with 
10% (w/v) ScBH (2% vol/vol) and subsequently used for mechanical SSA 
experiments. While spinning of the reaction mix worsened the amplification results 
(see above) a strong centrifugation of NBH alone engendered a notable difference 
regarding the observed optima of amplification. Most notably was the reduced 
intensity of reactions which were processed at frequencies of 756 Hz and 953 Hz. 
Morover, optima of amplification were observed at processing frequencies of 
600 Hz, 1,201 Hz, but also at 300 Hz (Figure 4.10). 
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Figure 4.9: Influence of centrifugation treatment, seed dilution and processing in SSA 
experiments 
   (A) A mixture of 2% (v/v) scrapie BH in NBH was used for mechanical SSA 
experiments. The reaction mix was centrifuged as indicated. The supernatant was 
used for conversion reactions. The PrP
res
 amplification is shown as a function of 
time. (B) Comparison of Sc237- or 263K-seeded reactions with and without 
processing steps; Reactions were either carried out in shear-generators or in 15 ml 
reaction tubes. The PrP
res
 amplification is shown as a function of time. (C) Seed 
dependency over time: As indicated Sc237BH was used in different dilutions 
(1:50 ≙ standard). The reactions were performed in the SSA array at 37°C for 
≥ 24 hours. Samples were run with a cycle setting of 5 sec processing and 5 min 
incubation. Modified reaction tubes were used to extract ~30 µl samples at 
different time points. Samples were digested witch 50 µg/ml proteinase K (PK) at 
37°C for 1 h and analyzed by western blotting using the PrP-specific 6H4 
antibody, followed by 1D densitometry. 
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Figure 4.10: Influence of  NBH centrifugation in SSA experiments 
   (A) Amplification of PrP
res
 in mechanical SSA reactions using the supernatant of 
spinned NBH. The reactions were seeded with Sc237 hamster prions. Data is 
shown as a function of rotation frequency and of time. (B) A corresponding kinetic 
trace of PrP
res
 amplification at the frequencies of 150 Hz, 300 Hz, 600 Hz and 
1201 Hz. (C) Corresponding western blots of the PK resistant PrP
res
 bands are 
shown for each time point. Directly after preparation aliquots of 2 ml 10% (w/v) 
brain homogenate were spinned at 25,000 x g  for 10 min at 4°C. The supernatant 
was used to prepare a mixture of 5% (v/v) scrapie BH in NBH for conversion 
reactions. The reaction were performed in the SSA array at 37°C for 48 hours. 
Samples were run with a cycle setting of 5 sec processing and 5 min incubation. 
Modified reaction tubes were used to extract ~30 µl samples at different time 
points. Samples were digested witch 50 µg/ml proteinase K (PK) at 37°C for 1 h 
and analyzed by western blotting using the PrP-specific 6H4 anti-body, followed 
by 1D densitometry. 
Conclusion 
Strong centrifugation of the reaction mixture potentially removed critical 
components for the amplification process and therefore leaded to flattened growth 
curves and decreased amplification factors. Similarly, if the supernatant of spun 
NBH is used, the disappearance of specific cell components might negatively 
influence the PrP
res
 buildup rates.  
4.3.6 Influence of SDS 
In conversion reactions of recombinant prion protein (for example in QuIC) slightly 
denaturant reaction conditions support the generation of PK-resistant particles.
204
   
Evidence for the influence of SDS on PMCA has also been given.
5
 Taking account 
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of different models for the conversion of PrP
C
 to its resistant isoform PrP
Sc
 a 
denaturing effect would primarily make sense if the  heterodimer model (Figure 1.4, 
p. 22) is assumed. If a transition state of PrP  is energetically supported by changed 
buffer conditions the heterodimer buildup increases and the equilibrium is shifted 
towards PrP
res
. Thus, the effect of a denaturing agent was surveyed in mechanical 
SSA reactions using 0, 1, 2.5 and 5 mM SDS at processing frequencies of 150 Hz 
and 1,201 Hz. While a concentration of 1 mM SDS reduced the conversion 
efficiency, no PrP
res
 could be detected in reactions with 5 mM SDS. (Figure 4.11) 
 
Figure 4.11: Effect of SDS on PMCA-based SSA reactions 
    Concentrations 0, 1, 2.5 and 5 mM SDS were tested in reactions processed with 
1,201 and 150 Hz. A mixture of 5% (v/v) scrapie BH in NBH was used for 
conversion reactions. Reactions were carried out in 8 Heidolph 3F shear-
generators with drilled outlet holes in the stator. The rotor blades were rounded 
down by manual grinding for smooth running behavior. The reaction were 
performed in the SSA array at 37°C for 48 hours with a cycle setting of 5 sec 
processing and 5 min incubation. Modified reaction tubes were used to extract 
~30 µl samples at different time points. Samples were digested witch 50 µg/ml 
proteinase K (PK) at 37°C for 1 h and analyzed by western blotting using the PrP-
specific 6H4 antibody, followed by 1D densitometry. 
Conclusion 
SDS clearly suppressed PrP
res
 amplification and is not necessary in mechanical SSA 
reactions. 
 
 
5 Discussion  
Based on the structural properties of proteopathic seeds we developed a concept for 
the in vitro selection of proteopathic seed populations from mixtures. Using the 
principle of a Couette-type shear generator
317
 (Figure 3.8, p. 58) we were able to use 
precisely adjustable seed fragmentation. The selection is enabled through the 
different mechanic fragmentability. While alternating periods of seed growth and 
selective shearing kinetically select seed populations which are optimally 
fragmented, seed populations with distinct mechanic fragmentability are supressed. 
Selective shearing amplification clearly revealed that the closely related hamster 
prion strains Sc237 and 263K can be distinguished by the kinetic analysis of in vitro 
selected PrP
res
. Furthermore, the data suggests the presence of multiple PrP
res
 
conformations within the prion isolate Sc237. Three processing frequencies of 
150 Hz, 600 Hz and 1,201 Hz were identified for optimal amplification of Sc237 
prion seeds with the mechanical approach (Figure 4.7, p. 75). Importantly, the 
provided data of acoustic SSA showed to be in line with the optima of amplification 
that were detected by mechanical shearing (Figure 4.3, p. 69). Therefore, kinetic 
seed selection might be independent of the selected shearing mechanism. 
Mechanical SSA not only provides an efficient technique to amplify PrP
res
, but also 
an exclusive way for kinetic seed amplification data acquisition. Thus, the kinetic 
PrP
res 
amplification traces were surveyed for both hamster prion strains and the 
experimental data provided clear evidence for characteristic differences: Contrary to 
Sc237, SSA reactions with 263K showed a significant lower initial buildup rate at 
the highest applied shear stress. Moreover, only one optimum near the maximal 
processing frequency was found (Figure 4.7, p. 75). Equally noteworthy is the 
observation that non-seeded reactions did not amplify detectable amounts of PrP
res
 
and an omission of processing leaded to significant lower PrP
res
 buildup rates 
(Figure 4.5 C, p. 72 and Figure 4.9 B , p. 80). On the one hand this confirmed that 
shearing does not induce or change the conformation of the used prion seeds, on the 
other hand it leads to the conclusion that conformationally different major PrP
res
 
populations exist. Thus, the conformation of the amplified PrP
res
 determined the 
time courses in these SSA experiments.  
Further evidences for the conformational discriminability of the closely related 
hamster prion strains 263K and Sc237 can be found in previous transmission 
experiments which were published in the year 200: A diversification of the Sc237 
hamster strain was also observed during transmission in mice. In conformity with 
the species barrier no clinical signs were observed within two years after 
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inoculation of the animals. Nevertheless, PrP
Sc
 deposits were found. In deed, the 
derived prions were infectious for mice and hamsters, even if it became apparent 
that the incubation times were relatively long.
184
 However, the attack rates were 
100% and the interspecies infectivity gives evidence for a heterogenity or, spoken 
otherwise, the evolution of a heterogeneous population of Sc237.
119
 The passage 
history of the utilized prion strains also supports these findings. Source of all used 
scrapie hamster and mouse strains was the Compton “Drowsy goat” passage line 
which originates form first goat passages of scrapie sheep brain homogenates.
319
 
Interestingly, a putative in vivo separation of scrapie agent strains from a mixture 
has already been discussed in the course of observed transmission barriers.
122,123
 
Contrary to Sc237 the agent strain 263K is the product of limited dilution passages 
in hamsters. (Figure 5.1) It is likely, that the existence of a single detectable PrP
res
 
population in 263K has its origin in a clonal selection of a single conformation 
during these in vivo transmission experiments. This implies that individual prion 
strains can be propagated in vivo while maintaining multiple PrP
Sc
 conformations, 
presumably in the absence of any obvious selective pressure.  
Then again, it was hypothized that the diversification of prion strains can be 
attributed to the presence of readily interconverting PrP
Sc
 conformations (cp. 1.3, 
p. 15 et seqq.).
119,140
 It was argued that a selective pressure promotes the 
amplification of minor prion populations to become the dominant species.
119,140
 This 
assumes that certain if not all prion strains show an intrinsic conformational 
heterogenity. Thinking this further, serial prion replication under an selective 
constraint would finally dilute out the minor or less fast replicating sub-types. 
Interestingly, it was demonstrated that specicif prion strain characteristics, which 
occurred under selective conditions in cell culture were regained if the exterior 
constraint was restricted. However, heterogenity was also observed if the particular 
strain was subsequently cloned by end-point dilution. Hence, it cannot be ruled out 
that the Sc237 strain consits of interconverting PrP
Sc
 types. This implies, that the 
multiple observed shear optima are caused by a conformational adaption to the 
specific applied shear forces. Similarly, the single shear optimum of the 263K strain 
might be explained by its low propensity to undergo a spontaneous strain 
conformational mutation. In order to exclude this possibility, mechanical SSA 
should be used to serially propagate PrP
Sc
 from the Sc237 strain at a specific 
selective processing frequency. Subsequently, SSA might be used to test for PrP
Sc
 
conformational selection: The generated reaction mixture could be split for 
processing across the entire accessible frequency range. A reoccurance of the three 
shear optima would, therefore, be indicative for the presence of ‘quasi-species’, 
while a single optimum would contradict this hypothesis. Moreover, the latter case 
would suggest a purification of an individual, conformational stable seed 
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population. Indeed, latest experiments give evidence for a successful isolation of a 
prion sub-population. Thus, in vivo selection of inherent strains is possible using 
kinetic seed selection.
316
  
 
Figure 5.1: Passage history of prion strains Sc237 and 263K 
Source of all used scrapie hamster and mouse strains was the Compton “Drowsy 
goat” passage line.319. Infective material was initially used for in vivo infection 
studies with mice in 1963.
320
 After subpassages in rats
43
 the agent was shown to 
produce disease in mice after five passages
321
. Using rat passaged (12
th
 passage) 
agent, strain adaption studies in syrian golden hamsters were performed, showing 
long incubation times of 11 months in first passage. After a second passage mean 
incubation times could be dramatically reduced to 4-5 months and two pools of 
infectious material were used for further passages in outbred hamsters and 
random-bred mice.
122,123,322
 A first passage of an isolate of the 2
nd
 hamster passage 
in mice showed large species barrier (302K), while one brain of the 3
rd
 hamster 
passage revealed high infectivity and low species barrier for mice (431K). 
Contrary to these findings no cases of scrapie developed if 6
th
 passage scrapie 
agent (or later) of the hamster passage line was used for inoculation in mice. This 
agent was designated 263K and showed constant incubation times and 
hisopathology, as proven by limited dilution studies (agent was cloned). All strains, 
including subsequent passages in mice (302K and 421K), were found to be clearly 
different from the Chandler (139A) main line of mouse passaged scrapie agent. 
Contrary to 263K the agent strain Sc237 was originally derived from the first rat-
to-hamster passage. After six passages in Lak/LHC inbred hamsters passaging was 
continued in Lak/LVG hamster and the agent was finally designated 
Sc237.
75,122,123,323–325
The most important difference, though, is that in these 
experiments no limited dilution was performed. (A) 
319
  (B) 
320
 (C) 
43
 (D/E) 
122,123,322
 
(F) 
75,122,123,323–325
; supplemented by information on the origin of the hamster prion 
strain Sc237 and further modified this illustration is from
122
. 
Considering current techniques in prion research our findings emphasize the 
potential of selective shearing amplification as a relatively fast method for seed 
characterization. Of course, several methods exist to characterize prion strains, for 
instance by receiving benefit from the different prion suceptibility of certain cell 
lines.
326–331
 The standard scrapie cell assay (SSCA), for example, helps to determine 
strain infectivity and the cell panel assay (CPA) showed its potential to determine 
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specific strain properties.
119,140,332–334
 However, cell-culture-based assays remain 
time consuming. The same applies to the analysis of strain specific incubation times 
as well as a comparison of vascular lesion distributions in anatomical defined 
regions (‘lesion profiles’) which are accompanied by long-lasting in vivo 
transmission experiments. Thus, mechanical SSA represents a fast method that 
allows to select seed conformations from mixtures by finely tuned shear induced 
fragmentation. Optimally fragmented seeds, thus, gain a selective advantage and 
become the dominant population of the in vitro conversion reaction. 
PMCA has been shown to serial replicate infectivity in vitro.
207
 Recent research also 
revealed that strain-specific incubation times in vivo correlate with elongation rates 
in vitro.
335
 It is therefore of prime interest to test the neurodegnerative potential of 
selectively amplified seeds in vivo. In addition, selectively amplified sub-
populations that were sub-passaged in animals could again be screened for potential 
changes in their kinetic buildup rates and their shear optima. Thus, SSA could be 
used to reveal putative conformational changes which might occur in vivo. This 
obviously presupposes the successful isolation of single seed populations. Once 
purified, seed populations could be surveyed in detail, for example using different 
conformational stability assays.  
Using PMCA it was also demonstrated that strains with fast elongation rates 
maintain their amplification yield irrespective of wether incubation time intervals 
between processing steps were varied. It was found that strain-specific elongation 
rates limit the overall amplification yield in a strain-dependent manner.
335
 However, 
an interprocessing delay in mechanical shearing amplification resulted in higher 
PrP
res
 amplification yields and a faster buildup rate for the Sc237 strain (Figure 4.8, 
p. 77). 
6 Outlook 
A conformational selective amplification technique might promote a clearer 
understanding of neurodegnerative proteopathic seeds. This aspect is not merely 
restricted to prions. Recombinant α-synuclein seeds induce protein deposition in 
vitro as well as Parkinson-like neurodegeneration in vivo.
336–338
 Similarly, 
Alzheimer peptide (Aβ) depositions could be induced in transgenic mice using brain 
tissue extracts of diseased Alzheimer patients and transgenic mice.
186,339
 Similar to 
prion strains, the source of the seed as well as the genetical preconditions influence 
the phenotypical expression.
186
 Nevertheless, there is clear evidence that specific 
molecular structures of proteopathic seeds have crucial influence on their 
propagation in vivo: For instance, the seeding effectivity of synthetic Aβ fibirls in 
vitro is not automatically accompanied with seeding activity in vivo. Sometimes in 
vivo transmissions showed to be directly successful and sometimes only large 
amounts of fibrils induce clinical signs in the animal model.
185,186
 Additionally, 
prion replication in vivo does not consequently lead to the occurance of clinical 
signs.
182–184
 Thus, only a limited number of certain conformations might go along 
with infectivity. Furthermore, the presence of more than one seed conformation 
might also be true for human neurodegenerative diseases like Alzheimer disease or 
Parkinson disease. Hence, the applicibility of SSA for the selective replication and 
structural investigation of neurodegeneration associated seeds remains to be tested. 
In this context a calculation of the actual shear stress values would represent a great 
benfit to define the structural stability of distinct seed populations. A mathematical 
solution is already available, but recommends a more simple tool geometry.
340
 
Therefore, a consistent further development of the shear-generators is reasonable. 
Further potential for optimization resides in the reaction composition and the 
reaction parameters: The total PrP
res
 amplification yield often decreased after 24 
hours (cp. Figure 4.9 D, p. 80). Although this phenomenon could be prevented 
using cycle time variations (Figure 4.8, p. 77), a further investigation is advisable. 
Additionally, a pretreatment of the tissue brain homogenates showed significant 
influence on the conversion reactions. Centrifugation of the reaction mixture leaded 
to a depletion of the PrP
res
 buildup rates; the same applies to a dilution of the seed 
(Figure 4.9 A, C and D, p. 80). Although these experiments provide an initial 
insight into the sensitivity of the assay, serial amplification might dramaticaly 
increase the amount of detectable protease resistant PrP.
208
 Interestingly, a 
pretreatment of NBH changed the observed shear optima. (Figure 4.10, p. 81). It 
was reported that the usage of purified PrP
C
 leads to better amplification results in 
PMCA.
209
 Thus, crude tissue homogenate might comprise conversion promoting as 
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well as obstructive factors, which promote or suppress the amplification of specific 
sub-populations. However, the effect of selective shearing should be tested using a 
purified substrate. Slightly denaturating conditions like in the presence of SDS seem 
to be mandatory for in vitro reactions such as QuIC or recPrP-PMCA
202,204
, 
presumably by promoting an intermediate conformation of PrP (cp. Figure 1.4, 
p. 22). Contrary to its effect in recombinant PrP conversion assays, SDS completely 
suppressed amplification of the Sc237 seed at 1,201 and 150 Hz in SSA. This might 
indicate that SDS has a different effect on native, glycosylated and GPI-anchored 
PrP
C
 than on recPrP. It is also likely that SDS disturbs the potential interaction of 
PrP
C
 with its proteinaceous environment. However, recent research clearly 
demonstrated the influence of detergents on PK-resistance. In particular, SDS was 
shown to weaken the PrP
res
 intensity on western blots after PK-digest.
341
 
The molecular structures of mammalian prions are still elusive, and a major 
bottleneck for their investigation by NMR-Spectroscopy is the availability of 
substantial amounts of isotopically labelled recombinant prions. In recent years 
solid progress has been made in the generation of infectious recombinant prions 
using an ultrasonic approach.
90,205
 Unfortunately, the PMCA technique is restricted 
to small reaction volumes. Thus, a further field of application of the SSA technique 
is the conversion of recombinant PrP. This thesis mainly focused on seeded 
conversion reactions, but also de novo generation of prions using PMCA was 
demonstrated
203
 and most recently detailed protocols were published to achieve de 
novo formation with PMCA.
231
 Interestingly, generation of infectivity was always 
accompanied with many serial amplification rounds. However, de novo  generation 
of PK resistant PrP is likely, either by spontaneous aggregation or applied shear 
stress, but were not observed in mechanical SSA experiments. Of course, serial 
passaging of non-seeded reactions might induce spontaneous aggregation and these 
experiments remain to be done.  
Although acoustic approach for selective shearing amplification was used several 
technichal drawbacks emphasize the advantages of mechanical shearing. Although 
cavitation bubbles within the reaction vials can be prevented if the sample positions 
are matched to Chladni pattern, the wear and tear of the sonotrode is anvoidable. 
The fast decay changes the oscillation behavior and necessitates an often exchange 
of the Cup Horn. Unfortunately, the oscillation pattern of each replica was unique 
(Figure 3.5, p. 54) and even sligthly changes in the symmetry were shown to have 
strong influence (Figure 4.3, p. 69). Furthermore, generated sound waves have to 
penetrate the wall of the reaction vials. Thus, refraction, reflection and interferrence 
might raise problems. Although thin-walled PCR-tubes were used, the application 
of other materials should be considered. The sound propagation in Teflon™ 
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(1.52 km/sec), for example, is similar to that in water (1.47 km/sec). Thus, Teflon™ 
might be a better choice.  
 
 
 
Appendix 
Detailed experiment parameters for PMCA, acoustic SSA and mechanic SSA are 
summarized below. (p. 89 et seqq.) 
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A list of PMCA experiments and further information regarding the execution are given in Table A.1. 
Table A.1:  Performed PMCA experiments and reaction parameters 
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1 
Seed dependence 
(till round 2) 
Sc237 40/60 90 0.25-10 100 24 - I O Figure 4.1, p. 66 
2 Position effects Sc237 40/60 90 5 100 24 - I O Figure 4.1, p. 66 
3 
Bicellar 
mixtures
3 Sc237 40/60 90 5 200 24 - I O Figure 4.1, p. 66 
4 
Radius 
dependence 
+ bicelles 
Sc237 40/60 90 5 100 48 - I R Figure 4.1, p. 66 
5 Height profile 
Sc237 
263K 
60/10 90 5  24 0.5; 3; 5; 7; 9 I H Figure 4.2, p. 67 
                                              
 
2
 O = original Misonix 4,000 setup (cp. 3.6.1, p. 44 et seqq. and Figure 3.3 A, p. 47); R = Radius dependence (centered rotating sample holder, cp. 3.6.1, p. 44 et seqq. and 
Figure 3.3 A, p. 47 B); H = height-adjustable sample holder (cp. 3.6.1, p. 44 et seqq. and Figure 3.3 A, p. 47 C) 
 
3
 Composition of bicellar mixtures is given in chapter 3.1.5, p. 36. Detailed information about used bicelle concentrations are listed in  
Table A.2, p. 106. 
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Used bicelle concentrations for experiments 3 and 4 (Table A.1) are listed below.  
 
Table A.2:  Applied bicelle concentrations in PMCA experiments 
Experiment Bicellar mixture  
[mM] 
DMPS  
[%] 
3 0; 25 0; 5; 10 
4 0; 25 - 
 
A list of all performed acoustic experiments and their reaction parameters is given in Table A.3. 
Table A.3:  Performed acoustic SSA experiments and reaction parameters 
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Sc237 
263K 
3/5 85 2 130 12 
0.5; 1; 1.5; 2; 
3; 4; 5; 6; 8; 
10; 12; 14; 
16; 18 
I Figure 4.3, p. 69 
2 Height profile 
Sc237 
263K 
3/5 85 2 130 12 
0.5; 1; 1.5; 2; 
3; 4; 5; 6; 8; 
II Figure 4.3, p. 69 
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A list of all performed mechanical SSA reactions is given in Table A.4. 
 
Table A.4:  Mechanical SSA reactions and reaction parameters 
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1 
Feasibility of conversion 
with shear-generators
5
 
- 
Sc237 
263K 
900 60/10 
0; 15; 30; 45; 60; 75 
krpm
5
 
24 1:10 Figure 4.4, p. 70 
2 
Test of the SSA array 
Frequency range 
- 
Sc237 
263K 
900 60/60 
40; 54; 72; 96; 129; 
173; 232; 311; 417; 
559; 749; 1,004 
24 1:10 Figure 4.5, p. 72 
3 Non-seeded reactions - - 900 60/10 54; 173; 417 22 - Figure 4.5, p. 72 
4 Cycle time + Sc237 1,150 5/5, 15, 30, 60, 90 1,000 40 1:50 Figure 4.6, p. 73 
5 Frequency range + 
Sc237 
263K 
1,150 5/5 
96; 119; 150; 189; 
238; 300; 476; 600; 
756; 953; 1,201 
22 1:50 Figure 4.7, p. 75 
          
                                              
 
4
 After ~1; 3; 6; 12; 24; 36 and 48 h samples of ~20 µl were taken from the reactions. The shape of the rotor blade edges was rounded down by manual grinding to avoid 
vibrations. 
5
 These initial reactions were performed with non-modified hardware from Heidolph (Silent Crusher S, 3F dispersion tool). Speed of rotation was only adjustable by a 
built-in potentiometer with a rough rpm scale. All other experiments were performed with modified hardware (SSA array) giving the possibility to adjust the frequency 
precisely. 
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6 
Continuously increased 
incubation time
6
 
+ Sc237 1,150 
Start value 5/5; 
end value 5/15 
96; 119; 150; 189; 
238; 300; 476; 600; 
756; 953; 1,201 
48 1:50 Figure 4.8, p. 77 
7 Non-processed reaction + 
Sc237 
263K 
1,150 5/5 - 24 1:50 Figure 4.9, p. 80 
8 Seed dilution + Sc237 1,150 5/5 600 24 
1:25-
1:225
7
 
Figure 4.9, p. 80 
9 
Centrifugation 
 of reaction mix
8
 
+ Sc237 1,150 5/5 1,000 48 1:50 Figure 4.9, p. 80 
10 Centrifugation of NBH
9
 + Sc237 1,150 5/5 96; 119; 150; 189; 48 1:50 Figure 4.10, p. 81 
                                              
 
6
 The increase of the cycle time is defined by 𝐶(𝑡) = 𝐶1 + (𝐶2 − 𝐶1)(1 − 𝑒𝑥𝑝 (−
1
𝐶𝑘∗𝑡
). C1 represents the start cycle time (t=0). C2 is the final cycle time and Ck 
determines the initial slope. For the presented experiment a setting of C1 = 5 min, C2 = 10 min and Ck = 18 was used. 
7
 A 10% (w/v) ScBH (Sc237) was diluted 1:25, 1:50, 1:75, 1:100, 1:125, 1:150, 1:175, 1:200 or 1:225 into a 10% (w/v) NBH. 
8
 A mixture of 2% (v/v) ScBH in NBH was centrifuged with 2,000; 5,000; 10,000; 15,000 and 25,000 x g for 10 min at 4 °C (+ one non-centrifuged experiment). 
Supernatant was used for conversion reactions. 
9
 Freshly prepared NBH was spinned at 25,000 x g for 10 min at 4 °C (splitted in two SS34 centrifugation tubes). Supernatant was mixed with ScBH and taken for the 
conversion experiment. 
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238; 300; 476; 600; 
756; 953; 1,201 
          
11 
Effect of SDS 
(0, 1, 2.5, 5 mM) 
+ Sc237 1,150 5/5 150; 1,201 48 1:50 Figure 4.11, p. 82 
Abbreviations           97                                  97 
Abbreviations 
139A Mouse prion strain (Chandler strain) 
22L Mouse prion strain 
263K Hamster prion strain 
79A Mouse prion strain  
Aβ Alzheimer peptide  
Bax Bcl-2-associated protein x 
Bcl-2 B-cell lymphoma 2 
BH Brain homogenate 
BH2 Bcl-2 homologue domain 2 
bPrP Bovine prion protein 
BSE Bovine spongiform encephalopathy 
CHAPS 3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate 
CHAPSO 3-[(3-Cholamidopropyl) dimethylammonio]-2-hydroxy-1-pro-
panesulfonate 
CJD Creutzfeldt-Jakob disease 
CMC Critical micelle concentration 
CMC Critical micelle concentration 
CPA Cell panel assay 
98 Abbreviations            Abbreviations 
CWD Chronic wasting disease 
DHPC Dihexanoylphosphatidylcholine  
DMPC Dimyristoylphosphatidylcholine  
DMPS Dimyristoylphosphatidylserine 
DNA Desoxyribonucleic acid 
Dpl Doppel protein 
DY Drowsy (hamster prion strain) 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
fCJD Familiar form of the Creutzfeldt-Jakob disease 
FFI Fatal familial insomnia 
Fyn A member of the Src tyrosine kinase family 
GITC Guanidinium thiocyanate 
GPI Glycosylphosphatidylinositol 
GSS Gerstmann Sträussler Scheinker syndrome 
hPrP Human prion protein 
hPrP Human prion protein 
HY Hyper (hamster prion strain) 
HZI Helmholtz-Centre for Infection Research, Braunschweig, 
Germany 
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HZI Helmholtz centre for infection research (ger. : Helmholtz-
Zentrum für Infektionsforschung; Braunschweig, Germany) 
iCJD Iatrogen form of the Creutzfeldt-Jakob disease 
LB Lysogeny broth 
LDS Lithium dodecyl sulfate 
MHM2 PrP Chimeric mouse hamster prion protein 
mPrP Mouse prion protein 
mPrP(121-230) Mouse prion protein (residues 121-230), recombinant 
mPrP(23-231) Mouse prion protein (residues 23-231), recombinant 
mPrP
C
 Cellular mouse prion protein 
MS Mass spectroscopy 
MW Molecular weight 
MWCO Molecular weight cut-off 
NADPH Nicotinamide adenine dinucleotide phosphate 
NaPTA Sodium (ger. : Natrium (Na)) phosphotungstic acid 
NBH Normal brain homogenate (healthy animal) 
NBH Normal brain homogenate 
Ni-NTA Nitrilotriacetic acid and Ni 
NMR Nuclear magnetic resonance 
NOG N-oxalylglycine 
100 Abbreviations            Abbreviations 
OD Optical density 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PK Proteinase K 
PK1[22L] Mouse prion strain 22L adapted to PK1-cells 
PK1-cells Porcine kidney epithelia cells 
PMCA Protein misfolding cyclic amplification 
PMCAb Protein misfolding cyclic amplification with beads 
PMSF Phenylmethylsulfonylfluorid 
Poly(A), 
poly(rA) 
Polyadenylic acid, polyadenylic ribonucleic acid 
POPG 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol 
Prnd Mouse gene encoding for doppel 
Prnp Mouse gene encoding for the prion protein 
PrP Prion protein 
PrP* A hypothetical intermediate form of the prion protein 
PrP
27-30
 Protease resistant core of protease K treated PrP
Sc
 or PrP
res
 
PrP
res
 Partially protease K resistant form of the prion protein 
PrP
Sc
 Disease associated isoform of the prion protein (Sc = scrapie). 
Major or only part of the prion. 
PrPβ A β-sheet rich isoform of the prion protein 
Abbreviations           101                                  101 
PrPβf A β-sheet-rich and fibril forming isoform of the prion protein 
PTFE Polytetrafluoroethylene 
QuIC Quaking induced conversion 
recPrP Recombinant prion protein 
recPrP-PMCA Recombinant prion protein – protein misfolding cyclic amplifi-
cation 
RML Rocky Mountain Laboratories prion strain (mouse) 
RML Rocky mountain laboratory mouse prion strain  
RNA Ribonucleic acid 
rPrP
Sc
 Protease K resistant form of PrP
Sc
 
RT Room temperature 
RT-QuIC Real time-quaking induced conversion 
RT-QuIC Real-time Quaking-induced conversion 
saPMCA Serial automated protein misfolding cyclic amplification 
Sc237 Hamster adapted prion strain 
Sc237BH Brain homogenate from Syrian golden hamsters which were 
infected with the hamster prion strain Sc237 
ScBH Scrapie brain homogenate 
ScBH Scrapie brain homogenate 
sCJD Sporadic form of the Creutzfeldt-Jakob disease 
SDS Sodium dodecyl sulfate 
102 Abbreviations            Abbreviations 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate-poly acryl amide gel electrophoresis 
shPrP Syrian Golden hamster prion protein 
shPrP(23-231) Full length Syrian Golden hamster prion protein (residues 23-
231), recombinant  
SOD Superoxide dismutase 
sPrP
Sc
 Protease K sensitive form of PrP
Sc
 
Src Sarcoma tyrosine kinase 
SSA Selective shearing amplification 
SSA Selective shearing amplification 
SSCA Standard scrapie cell assay 
Swa Swainsonine, a Golgi α-mannosidase II inhibitor, which is cap-
able to inhibit prion infections in cell culture 
TBST Tris-buffered saline and Tween 20 
TSE Transmissible spongiforme encephalopahty 
vCJD Variant form of the Creutzfeldt-Jakob disease 
β2m β2-microglobulin 
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